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General introduction
Bladder cancer is a major health problem. According to the nation-
wide Netherlands Cancer Registry, bladder cancer accounted for 
6,149 new cases in the Netherlands in 2011, which was 5.4% of all 
newly diagnosed cancers that year. The age-adjusted (to the Europe-
an population) incidence rate per 100,000 person-years was 45.2 in 
men and 11.5 in women in 2011[1]. The incidence of bladder tumours 
is increasing, and consequently the financial burden of its diagnosis, 
treatment and follow-up is rising. Bladder cancer entails a very high 
per-patient cost from diagnosis to death. In fact, the cost per patient 
with bladder cancer is the highest of all cancers [2] due to the life-
long need to monitor for and treat recurrent tumours.
The most common histological subtype of bladder cancer is urothe-
lial carcinoma, accounting for more than 90-95% of all bladder tu-
mours [3]. Approximately 75-85% of patients with bladder cancer 
presents with non-muscle invasive bladder cancer (NMIBC), i.e., Ta, 
T1, and carcinoma in situ (CIS). The remainder of patients present 
with tumours invading the detrusor muscle (stage T2), the perives-
ical tissue (T3), or the organs surrounding the bladder (T4) (figure 
1) [4]. Stage Ta tumours have a papillary configuration of their ex-
ophytic part, are confined to the urothelium, and do not penetrate 
into the lamina propria or detrusor muscle. Stage T1 tumours orig-
inate from the urothelium but penetrate the basement membrane 
which separates the urothelium from the deeper layers. They invade 
into the lamina propria, but do not reach the detrusor muscle.
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Figure 1: TNM staging of bladder cancer [4]. Adapted from Verma 
et al. [37].
Currently, two classifications are used for grading of papillary NMIBC 
(WHO 1973 and 2004; table 1) [5]. 1973 WHO grade 1 carcinomas have 
been reassigned to papillary urothelial neoplasms of low malignant 
potential (PUNLMP) and low-grade carcinomas in the 2004 WHO 
classification. Grade 2 carcinomas, which were the subject of con-
troversy, have been eliminated in the 2004 WHO classification and 
have been reassigned to low-grade or high-grade carcinomas. The 
2004 WHO classification contains a detailed histological description 
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of the various grades, which should result in less diagnostic variabil-
ity among pathologists, however, the published comparisons have 
not clearly confirmed a better reproducibility for the WHO 2004 
classification [6,7]. Several studies have compared the two classifica-
tions concerning prognostic implications with conflicting results [7-
11]. Until the prognostic role of this classification has been validated 
by more prospective trials with sufficient follow-up, both classifica-
tions should be used, as indicated by the 2013 European Association 
of Urology (EAU) guideline on NMIBC as a grade A recommendation 
[12]. Moreover, the majority of clinical trials published so far have 
been performed using the 1973 WHO classification, and therefore ad-
vises in currently used guidelines are based on this version.
Table 1: World Health Organization (WHO) grading 1973 and 2004 
[5].
1973 WHO grading
Urothelial papilloma
Grade 1: well differentiated
Grade 2: moderately differentiated
Grade 3: poorly differentiated
2004 WHO grading
Urothelial papilloma
Papillary urothelial neoplasm of low malignant potential (PUNLMP)
Low-grade papillary urothelial carcinoma
High-grade papillary urothelial carcinoma
CIS is a high-grade (anaplastic) carcinoma confined to the urotheli-
um, but with a flat non-papillary configuration. Unlike a papillary 
tumour, CIS appears as reddened and velvety mucosa and is slight-
ly elevated, although sometimes not visible. The diagnosis of CIS is 
based on the histology of biopsies from the bladder wall.
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The standard initial therapy for Ta and T1 papillary bladder tumours 
is complete macroscopic transurethral resection (TURBT) including 
a part of the underlying muscle [13,14]. This allows for the initial 
staging that is critical for further management decisions. A re-resec-
tion is advised if there is any doubt about the completeness of the 
initial TURBT, or if there was no muscle in the specimen (with the 
exception of Ta grade 1 tumours and primary CIS). In all T1 and/or 
grade 3 tumours a restaging second TURBT should be performed 2-6 
weeks after the initial TURBT [15], except for patients with CIS alone. 
Since there is considerable risk for recurrence and/or progression 
of tumours after TURBT, perioperative and/or adjuvant intravesical 
therapy is recommended. As NMIBC is a heterogeneous disease, in-
travesical therapy is risk group adapted. Risk stratification depends 
on clinical (number of tumours, tumour size, prior recurrence rate), 
and pathological (T category, CIS, grade) factors. The European Or-
ganization for Research and Treatment of Cancer Genitourinary 
(EORTC-GU) group has developed a scoring system and risk tables 
that predicts separately the risks of recurrence and progression in 
individual patients at different intervals after TURBT [16]. The EAU 
guideline [12] recommends stratification of patients into three risk 
groups and provides practical treatment recommendations (table 2). 
The stratification is based on the EORTC-GU risk tables and on the 
advises of the International Bladder Cancer Group [17], and is rath-
er similar to the American Urological Association (AUA) risk group 
stratification [18].
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Table 2: Treatment recommendations in NMIBC according to risk group 
stratification. 
Risk category Definition Treatment recom-
mendation
Low Primary, solitary, Ta, 
G1 (low grade), < 3 
cm, no CIS
One immediate in-
stillation of chemo-
therapy
Intermediate All cases not defined 
in the two adjacent 
categories
One immediate in-
stillation of chemo-
therapy followed by 
further instillations, 
either chemotherapy 
for a maximum of 
1 year or 1 year full-
dose BCG
High Any of the following:
• T1
• G3 (high grade)
• CIS
• multiple and 
 recurrent and large 
(> 3 cm) 
 TaG1-2 tumours (all 
conditions must be 
presented) 
Full-dose BCG 
instillations for 1-3 
years or cystecto-
my (in highest risk 
tumours)
Patients at low risk for both recurrence and progression, with a 
primary, solitary, small (< 3 cm), low grade Ta tumour without CIS, 
should receive one immediate post-TURBT intravesical instillation 
with a chemotherapeutic agent (i.e., mitomycin C, epirubicin) [19]. 
No further treatment is recommended prior to recurrence.
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In patients with intermediate-risk tumours (i.e., all cases between 
categories of low- and high-risk), the use of one immediate postop-
erative instillation of chemotherapy is not supported by consistent 
data [20], however still recommended in the EAU guideline. Adjuvant 
intravesical therapy is necessary but consensus regarding the opti-
mal drug and the most appropriate scheme is lacking. Intravesical 
immunotherapy with bacillus Calmette-Guérin (BCG) maintenance 
therapy shows a better reduction of the recurrence rate, but the im-
pact on tumour progression is uncertain [21-24]. Moreover, BCG-re-
lated side effects are more severe and more frequent as compared to 
chemotherapy [25,26]. In case adjuvant intravesical chemotherapy 
is administered, the schedule is optional although the duration of 
treatment should not exceed one year [27].
Patients with TaT1 high grade tumours with or without CIS and 
those with CIS alone are at high risk of progression. The value of one 
immediate instillation is at least doubtful, and, for example, certain-
ly not supported by the most recent recommendations of the ICUD 
(International Consensus on Urological Diseases) on bladder cancer 
[28].
Adjuvant intravesical BCG maintenance therapy for at least one year 
is the treatment of choice [23,24]. BCG maintenance for three years 
reduces recurrences as compared with one year, however the benefit 
of the two additional years should be weighed against its addition-
al costs, side effects, and inconvenience [29]. Immediate cystectomy 
should be considered in patients at highest risk of tumour progres-
sion [12,30].
Unfortunately, a substantial percentage of treated patients still ex-
periences tumour recurrences or even progression to muscle inva-
sive bladder cancer. This suboptimal treatment outcome can partly 
be attributed to low compliance with bladder cancer guideline ther-
apy advises. For example, Witjes et al. [31] found a marked underuse 
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of guideline-recommended adjuvant intravesical therapy in patients 
with intermediate- and high-risk NMIBC in a retrospective chart 
review study. Only 50% of high-risk patients received BCG mainte-
nance therapy as recommended by the EAU and AUA guidelines. 
In intermediate-risk patients, only 47% received AUA or EAU guide-
line-recommended adjuvant intravesical therapy. 24% of intermedi-
ate-risk patients and 9% of high-risk patients received only TURBT, 
with no further intravesical therapy. These findings are consistent 
with other studies that have found poor adherence to bladder cancer 
guidelines and underuse of BCG [32-36].
However, even with the use of adjuvant intravesical treatment as 
recommended in current guidelines, the number of recurrences 
and progression is still substantial. A recent large EORTC-GU study 
of maintenance BCG in intermediate- and high-risk TaT1 papillary 
bladder tumours with a median follow-up of 7.1 year showed a re-
currence in 587 of 1,355 patients (43.3%). Progression to muscle inva-
sive disease (≥ pT2) was seen in 109 (8.0%) patients and 67 (4.9%) 
developed distant metastases. A total of 68 patients (5.0%) died due 
to bladder cancer [29]. Progression rates for high-risk patients will 
obviously be even higher than for this mixed group of intermediate- 
and high-risk patients (only 41.3% of patients in this study had T1 
and/or grade 3 tumours and CIS patients were excluded).
BCG is considered to have failed whenever (1) muscle-invasive tu-
mour is detected during follow-up; (2) high-grade papillary NMIBC is 
present at 3 months; (3) CIS (without concomitant papillary tumour) 
is present at both 3 and 6 months. In patients with CIS present at 3 
months, an additional BCG course can achieve a complete response 
in > 50% of cases; or (4) any worsening of disease occurs under BCG 
treatment such as higher number of recurrences, higher T stage or 
higher grade, or appearance of CIS, despite an initial response [12]. 
Patients failing on BCG immunotherapy are unlikely to respond to 
further BCG therapy, and there are no standard accepted alternative 
22
bladder-preserving strategies available. This still is a highly unmet 
clinical need, and research into this area should be and is done. Cur-
rently, in this patient group, radical cystectomy still is indicated [12]. 
However, radical cystectomy is major surgery and not a suitable 
treatment option for a subset of patients.
In conclusion, initial therapy of NMIBC is transurethral resection, 
followed by intravesical chemotherapeutic or immunotherapeutic 
therapy. Drugs and treatment schedule are risk group adapted and 
described in guidelines. However, due to a low compliance to follow 
guideline therapy advises and even with the use of adjuvant intra-
vesical instillations, a substantial percentage of treated patients still 
experiences tumour recurrences or even progression to muscle in-
vasive bladder cancer. In patients failing on intravesical BCG there is 
no accepted standard alternative conservative approach. Moreover, 
current intravesical therapy is not without toxicity and serious local 
and systemic adverse effects may occur. Therefore, current intraves-
ical treatment strategies against NMIBC are suboptimal. To reduce 
toxicity and to enhance efficacy improved new intravesical treat-
ment modalities are urgently needed.
Outline of the thesis
In this thesis the preclinical testing of several potential new intra-
vesical treatment modalities for NMIBC are described. In chapter 2 
the relative cell killing effect of meso-tetraphenyl chlorin disulpho-
nate (TPCS2a)-based photodynamic therapy is described for 4 human 
bladder cancer cell lines and a rat bladder cancer cell line. Secondly, 
enhanced cytotoxicity of bleomycin was studied with TPCS2a-based 
photochemical internalization. Three commonly used anti-bladder 
cancer intravesical chemotherapeutic agents (i.e., epirubicin, gem-
citabine and mitomycin C) were used as controls. In this unique 
procedure site-specific delivery of several types of membrane-im-
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permeable molecules (e.g., bleomycin) to the cytosol of target cells 
(e.g., tumour cells) can be achieved. The technology is based on pho-
tochemical-induced release of endocytosed macromolecules from 
endosomes and lysosomes into the cytosol.
While in vitro models are useful for initial development and evalua-
tion of therapeutic agents and modalities, adequate animal models 
are still essential in the preclinical development of new effective and 
safe therapies for many human malignancies. To enable preclinical 
testing of new intravesical therapeutic agents, a suitable bladder 
tumour model that resembles human disease is highly desirable. In 
chapter 3 the problems associated with current in vivo animal blad-
der tumour models are discussed, focusing on the orthotopic syn-
geneic rat bladder tumour model. In the second part of the chapter 
the development of a potential new orthotopic rat bladder tumour 
model is described.
In chapter 4 the results of an efficacy and safety study with differ-
ent formulations of the relatively new drug apaziquone in the ortho-
topic Fischer/AY-27 rat bladder cancer model are discussed. Although 
the activity of intravesical apaziquone has been demonstrated in 
clinical marker lesion studies, to date apaziquone has not been test-
ed in orthotopic bladder cancer models. Moreover, during clinical 
development of apaziquone, buffer composition of the formulation 
was slightly modified, in order to get a better lyophilized product. Al-
though these modifications were not expected to affect the anti-tu-
mour activity of apaziquone, formal evidence was lacking and it was 
therefore considered important to examine the activity of different 
formulations.
The antiproliferative effect of protodynamic therapy with cis-uro-
canic acid (cis-UCA) against bladder cancer cells is discussed in 
chapter 5. Protodynamic therapy is a recently introduced concept 
of cancer treatment which comprises the inhibition of cancer cell 
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proliferation by intracellular acidification leading to apoptosis and 
cell death. Cis-UCA acts as a protodynamic drug capable of trans-
porting protons from the mildly acidic extracellular medium into 
the tumour cell cytosol. Safety and anti-tumour activity of repeated 
intravesical cis-UCA administration were assessed in the orthotopic 
Fischer/AY-27 rat bladder urothelial carcinoma model.
The results of a preclinical study in pigs are discussed in chapter 6. 
R-837 is the lead compound of the imidazoquinoline family (Toll-like 
receptor-7 (TLR-7) agonists). Activation of TLR-7 by R-837 leads to an 
intracellular signaling cascade, causing a potent anti-tumour im-
mune response. Imidazoquinolines also have potent direct biological 
effects on urothelial carcinoma cells by decreasing cell viability and 
inducing apoptosis and cytokine production. Additionally, initial re-
sults in an immune competent, orthotopic mouse model suggested 
anti-tumour effects in vivo. Therefore, imidazoquinolines may have 
therapeutic potential as intravesical agent for bladder cancer. To test 
whether R-837 might be suitable for bladder cancer therapy, TLR-7 
expression in human bladder cancer and normal bladder tissue is as-
sessed. To test the potential of R-837 for intravesical use, a pig model 
was used to study pharmacokinetic properties and toxicity of three 
different intravesical formulations with R-837.
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Abstract
Objective
In this in vitro study, we determined whether meso-tetraphenyl 
chlorin disulphonate (TPCS2a)-based photochemical delivery of bleo-
mycin was able to potentiate the cytotoxicity of bleomycin on blad-
der cancer cells.
Materials and methods
The human RT4, RT112, 253J, T24, and rat AY-27 urothelial carcinoma 
cell lines were used. Cells were seeded in 96-well plates. TPCS2a was 
added to the growth medium and the plates were incubated over-
night. Cells were then resuspended in TPCS2a-free culture medium 
and incubated for 3 hours. Subsequently, cells were treated for 60 
minutes with increasing doses of epirubicin, gemcitabine, mitomy-
cin C, or bleomycin followed by illumination for different periods. 
Cell viability was measured with a colorimetric assay after 72 hours.
Results
For the single treatments, in all 5 cell lines a dose-dependent inhi-
bition of cell proliferation was observed. This was seen both after 
treatment with TPCS2a-based photodynamic therapy (PDT), as well 
as after treatment with either bleomycin or one of the control chem-
otherapeutic agents. 
After treatment with PDT (240-s illumination), bleomycin 9.0 µM, 
and the combination of these treatments, relative survival percent-
ages were 89.2 ± 13.0, 70.2 ± 8.9, and 30.5 ± 6.1, respectively, in the T24 
cell line. After treatment with PDT (120-s illumination), bleomycin 27 
µM, and the combination of these treatments, relative survival per-
centages were 93.6 ± 15.7, 74.7 ± 9.6, and 30.0 ± 11.1, respectively, in 
the AY-27 cell line. In both cell lines, PDT combined with bleomycin 
showed significantly (P < 0.001) higher cell kill than the sum of the 
single treatments, suggesting a photochemical internalization effect.
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Conclusions
TPCS2a-based photochemical internalization of bleomycin showed 
a significant, at least, additive antiproliferative activity against hu-
man and rat urothelial carcinoma cells in vitro. Thus, photochemical 
internalization may have therapeutic potential as an intravesical 
strategy against bladder cancer. As the effect is heterogeneous, bi-
omarker studies are warranted to be able to predict the effects of a 
photochemical internalization-based treatment.
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Introduction
The initial treatment of non-muscle invasive bladder cancer (NMIBC) 
is transurethral resection, followed by intravesical therapy (i.e., 
chemotherapy or immunotherapy) [1]. However, intravesical thera-
py is not without toxicity, and a substantial percentage of treated 
patients still experiences tumour recurrences or progression to mus-
cle-invasive bladder cancer. Therefore, improved treatment modali-
ties are urgently needed.
Photodynamic therapy (PDT) is a potential treatment modality for 
NMIBC. PDT involves the administration of a photosensitizer and its 
subsequent activation by light of an appropriate wavelength. The 
result is the destruction of cells containing the photosensitizer. Clin-
ical trials with PDT have shown promising results in the treatment 
of bladder cancer [2,3]. Photochemical internalization (PCI) is a new 
technology that can be regarded as an enhanced PDT modality. PDT 
and PCI share many fundamental photodynamic properties, but PCI 
acts as a light-directed drug-delivery system by triggered release 
of endocytosed macromolecules into the cytosol [4,5]. Thus, PCI can 
help therapeutic molecules reach their intracellular target of action, 
realizing their therapeutic potential, instead of being degraded by 
lysosomal hydrolases. The PCI effect is achieved by photosensitizing 
compounds specifically localizing in the membranes of endocytic 
vesicles, destroying these membranes by an oxidative process after 
illumination.
Bleomycin is used in multiple, standard cancer chemotherapy regi-
mens, it has also been studied as intravesical treatment for NMIBC 
with only limited success [6,7]. The hydrophilic and relatively large 
chemical structure limits bleomycin’s ability to penetrate membra-
nous structures, but in many cell types bleomycin can be taken up by 
endocytosis. In this case, bleomycin accumulates in endocytic vesi-
cles, where it may be degraded; or it can enter slowly into the cytosol, 
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where it can be degraded by bleomycin hydrolase before reaching its 
therapeutic target in the nucleus. However, bleomycin cytotoxicity 
is highly increased when the cytosol is exposed to similar amounts 
of bleomycin following electroporation [8]. Thus, bleomycin may be-
come a very efficient and specific chemotherapeutic agent when it 
is combined with a treatment modality that activates its therapeutic 
potential only in the target environment. PCI of bleomycin inhibits 
tumour growth in different animal tumour models in a synergistic 
fashion [9,10].
Firstly, as bladder cancer is potentially well suited for effective treat-
ment by PCI because it is easily accessible for both intravesical in-
stillation and illumination, we studied the relative cell- kill effect of 
meso-tetraphenyl chlorin disulphonate (TPCS2a)-based PDT [11] in 4 
human bladder cancer cell lines and a rat bladder cancer cell line 
(anticipating future animal studies). Secondly, we studied whether 
TPCS2a-based photochemical delivery of bleomycin potentiated the 
cytotoxicity of bleomycin on these bladder cancer cell lines. Three 
commonly used anti-bladder cancer intravesical chemotherapeutic 
agents (i.e., epirubicin, gemcitabine, and mitomycin C) were used as 
controls.
Materials and methods
Cell lines and culture conditions
The human urothelial carcinoma (UC) cell lines RT4, RT112, 253J, T24 
[12], and rat UC cell line AY-27 (kindly provided by Dr. Ronald Moore, 
University of Alberta and Cross Cancer Institute, Edmonton, Alberta, 
Canada) were grown as a monolayer culture in RPMI-1640 medium 
with L-glutamine (Invitrogen, Carlsbad, CA, USA), supplemented with 
10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA), penicillin 
G (100 U/mL) and streptomycin (100 µg/mL) (Invitrogen) at 37°C in 
a humidified 95% air/5% carbon dioxide atmosphere. Medium was 
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changed twice weekly and cells were passaged using trypsin ethyl-
enediaminetetraacetic acid (Invitrogen) when confluent.
Chemotherapeutic- and TPCS2a-based PDT experiments
For TPCS2a-based photodynamic treatments, cells were harvested, 
washed, resuspended and plated at 1.0 x 104 cells per well in 96-well 
microtiter plates (Corning Inc. Corning, NY, USA; black plate, clear 
bottom). TPCS2a, (supplied by PCI Biotech AS, Oslo, Norway) was add-
ed at a final concentration of 0.2 µg/mL, and the plates were incu-
bated overnight. Cells were then washed 3 times with TPCS2a-free 
culture medium, resuspended in TPCS2a-free culture medium and 
incubated for 4 hours. Cells were then illuminated for different peri-
ods (0-10 min), using a LumiSource® illumination device (PCI Biotech 
AS, Oslo, Norway). LumiSource® was delivered with a bank of four 
light tubes (4 x 18 W Osram L 18/67, Blue) emitting mainly blue light 
with a peak wavelength of approximately 420 nm, with an average 
irradiance of 13.5 mW /cm2.
For combination therapy experiments, cells were prepared as de-
scribed previously and after incubation in TPCS2a-free culture medi-
um for 3 hours, cells were subsequently exposed to increasing doses 
of epirubicin (Pfizer bv, Capelle a/d IJssel, The Netherlands) (0-48.6 
µM), gemcitabine (Sun Pharmaceutical Industries Europe B.V., Hoof-
ddorp, The Netherlands) (0-65.6 µM), mitomycin C (Kyowa Hakko 
Kirin Co Ltd., Tokyo, Japan) (0-65.6 µM), or bleomycin (Euro Nippon 
Kayaku GmbH, Frankfurt, Germany) (0-81.0 µM). All solutions were 
prepared on the day of use. After incubation for 1 more hour, the 
cells were illuminated for different periods (0-5 min) as described 
earlier. After illumination, cells were washed 3 times with culture 
medium. Cell proliferation was measured after 72 hours. Treatment 
doses used in these studies were selected to evaluate whether ad-
ditive effects occurred and were not optimized for treatment out-
come.
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3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) 
assay
The effect of chemotherapy and PCI was determined by MTT as-
say. 72 hours after treatment, 30 µL of 5 mg/mL MTT solution (Sig-
ma-Aldrich) prepared in phosphate-buffered saline was added to 
the medium. Blue dye taken up by the cells after 4 hours of incuba-
tion was dissolved in dimethyl sulfoxide (100 µL per well) and opti-
cal density at 595 nm was read on an automated microplate reader 
(BioRad 3550, BioRad Laboratories, Hercules, CA, USA). The bleomy-
cin experiments were performed in quadruplicate and repeated one 
time by another laboratory worker; the control experiments with 
epirubicin, gemcitabine, and mitomycin C were performed at least 
once in quadruplicate.
Statistical analysis
In each combination experiment (with epirubicin, gemcitabine, mi-
tomycin C, and bleomycin), the Wald test was used to test for sta-
tistical significance of differences in relative cell survival between 
the treatment groups (control, PDT alone, chemotherapy alone, and 
combination). P < 0.05 was considered statistically significant.
Results
Chemotherapeutic- and TPCS2a-based PDT single treatment effects
PDT alone showed a clear phototoxic illumination time-dependent 
inhibition of cell proliferation in all 5 cell lines (figure 1). The viabil-
ity of all cell lines was reduced to < 40% of control with 360-second 
illumination. A further increase of the light dose resulted in approxi-
mately 99% cell death at 600 seconds (data not shown).
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Figure 1: Relative survival of human 253J, RT4, RT112, and T24 and 
rat AY-27 urothelial carcinoma cells after TPCS2a-based photody-
namic treatment. The cells were incubated with TPCS2a at 0.2 µg/mL 
for 24 hours, washed and incubated for 4 more hours in TPCS2a-free 
culture medium and subsequently illuminated. Relative cell survival 
was assessed 72 hours later. The percentage (mean ± SD) of viable 
cells from the corresponding control is shown. SD = standard devi-
ation.
TPCS2a pretreatment followed by chemotherapy treatment alone 
(without illumination) demonstrated a clear dose-dependent inhibi-
tion of cell proliferation in all 5 cell lines tested (figure 2).
Chemotherapeutic- and TPCS2a-based PDT combination effects
To evaluate the PCI therapy effect, chemotherapy was combined 
with TPCS2a and light treatment (figure 2). Combination of PDT and 
bleomycin was clearly superior to the single treatment modalities in 
the human T24 cell line and the rat AY-27 cell line, indicating at least 
an additive effect, suggesting a PCI effect. In contrast, additive treat-
ment effects were observed for the other treatment regimens and in 
the other cell lines, as indicated by the parallel dose-response curves.
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Figure 2: Relative survival of human 253J, RT4, RT112, and T24 
and rat AY-27 urothelial carcinoma cells after TPCS2a-based photo-
dynamic treatment in combination with epirubicin, gemcitabine, 
mitomycin C, or bleomycin. The cells were incubated with TPCS2a at 
0.2 µg/mL for 24 hours, washed and incubated for 3 more hours in 
TPCS2a-free culture medium and subsequently treated with an in-
creasing dose of epirubicin, gemcitabine, mitomycin C, or bleomy-
cin. After incubation for 1 more hour, the cells were illuminated with 
increasing illumination times (0-300 s). Cells were then washed and 
incubated again. Relative cell survival was assessed 72 hours later. 
The percentage (mean ± SD) of viable cells from the corresponding 
control is shown. The curves with 0 seconds of illumination repre-
sent the dose-response curves after treatment with chemotherapy 
alone. SD = standard deviation.
The treatment effects of PDT combined with bleomycin and PDT 
combined with epirubicin, gemcitabine, or mitomycin C in the T24 
and AY-27 cell lines are shown in figure 3. To be able to compare the 
4 individual chemotherapeutic agents, we selected the chemothera-
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peutic doses with a relative cell survival of > 70%: epirubicin 5.4 µM, 
gemcitabine 0.8 µM, mitomycin C 65.6 µM, and bleomycin 9.0 µM 
for the T24 cell line and epirubicin 0.2 µM, gemcitabine 0.3 µM, mi-
tomycin C 0.8 µM, and bleomycin 27 µM for the AY-27 cell line. As 
shown in figure 3, PDT combined with any chemotherapeutic drug 
showed a significantly higher cell kill compared with PDT alone in 
both cell lines (P < 0.05). Similarly this combination was superior to 
chemotherapy alone (P < 0.05), except for epirubicin and gemcit-
abine treatment in the AY-27 cell line. PDT combined with bleomycin 
showed significantly (P < 0.001) higher cell kill than the sum of the 
single treatments in both cell lines, suggesting a PCI effect.
Figure 3: TPCS2a-based photodynamic therapy in combination with 
epirubicin, gemcitabine, mitomycin C, and bleomycin in the human 
T24 cell line and the rat AY-27 cell line. The highest chemotherapeu-
tic doses (for chemotherapy alone) with a relative cell survival of > 
70% were selected, i.e., epirubicin 5.4 µM, gemcitabine 0.8 µM, mi-
tomycin C 65.6 µM, and bleomycin 9.0 µM in the T24 cell line and 
epirubicin 0.2 µM, gemcitabine 0.3 µM, mitomycin C 0.8 µM, and 
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bleomycin 27 µM in the AY-27 cell line. The chemotherapy bars rep-
resent the relative cell survival percentages after treatment with 
these doses. The PDT bars represent the relative cell survival percent-
age in the combination experiments (without chemotherapeutics) 
after 240-seconds illumination in the T24 cell line and after 120-sec-
onds in the AY-27 cell line. These illumination times were selected 
because with these light doses the differences in relative cell survival 
are most clear. The combination therapy bars represent the relative 
cell survival percentages after the combination treatment with the 
selected chemotherapy and light doses. With these doses, any fur-
ther added toxicity from the combination therapy can be detected 
and a comparison of the different combinations can be made. Each 
bar represents the percentage (mean + SD) of viable cells from the 
corresponding control. * P < 0.001, compared with the sum of the 
single treatments. SD = standard deviation.
Discussion
In this in situ study, we evaluated the therapeutic potential of 
TPCS2a-based photochemical delivery of bleomycin in 4 human blad-
der cancer cell lines and a rat bladder cancer cell line. In the T24 and 
AY-27 cell lines, a significant and at least additive antiproliferative 
effect of the combined PDT and bleomycin treatment was observed, 
a clear indication of the PCI effect. For all the single treatment regi-
mens, a clear dose-dependent inhibition of cell proliferation was ob-
served for all 5 cell lines.
Chemotherapeutics require efficient penetration into the cytosol of 
the tumour cells to reach their intracellular targets and exert their 
therapeutic activity. The prerequisite to penetrate the plasma mem-
brane limits the exploitable chemical structure of chemotherapeu-
tic agents to mostly small and lipophilic compounds penetrating 
the plasma membrane by passive diffusion. In addition, drugs (also 
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more hydrophilic drugs) can be taken up by means of various trans-
porters, e.g., gemcitabine [13].
The PDT mechanism relies on the in situ generation of cytotoxic 
agents by the activation of a light-sensitive drug, resulting in cell 
death [14]. The PCI technology is based on the same principles as PDT, 
i.e., the activation of a photosensitizer by light followed by formation 
of reactive oxygen species. Unlike PDT, the concept of PCI is based on 
the use of designed photosensitizers that localize preferentially in 
the membranes of endocytic vesicles of the targeted cells. The most 
efficient PCI photosensitizers have an amphiphilic structure (e.g., 
TPCS2a [11]) with a hydrophilic part inhibiting penetration through 
cellular membranes. The site-specific PCI-induced drug delivery adds 
to the well described cytotoxic [14], vascular, and immunostimula-
tory effects of PDT. PCI of bleomycin has already shown to induce 
a synergistic inhibition of tumour growth in vivo [9,10]. Adigbli et 
al. [15] demonstrated an increased cytotoxic (i.e., PCI) effect of the 
chemotherapeutic agent mitoxantrone combined with the photo-
sensitizer hypericin and illumination against multidrug-resistant 
bladder cancer cells. In general, PCI has the potential to reduce the 
systemic side effects of anticancer cytotoxic agents by reducing the 
drug dose required for a given effect and by conferring an increased 
level of treatment selectivity as the cytotoxic effect would be great-
est in areas that are illuminated, decreasing systemic toxicity [16], in 
line with our observations.
A prerequisite for PCI is that the molecule of interest is accumulated 
in endocytic vesicles at some stage in the process. We cannot pre-
clude that our results are the consequence of off-target effects as in-
ternalization of the chemotherapeutics was not studied here. How-
ever, bleomycin is a widely used chemotherapeutic agent for several 
types of cancer (e.g., testicular cancers, malignant lymphomas and 
squamous cell carcinomas of the cervix, and head and neck cancers), 
with endocytosis being an important uptake mechanism [8], proba-
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bly because of its hydrophilic and relatively large chemical structure 
(molecular weight: 1,415.6 Da). Thus, not unexpectedly we observed 
the most pronounced PCI effects with bleomycin. The lower PCI ef-
fects seen for the other chemotherapeutics are most likely the conse-
quence of their lower molecular weight and higher hydrophobicity, 
or their cellular uptake is dependent on the activity of transport pro-
teins, promoting easier cytoplasmic accumulation.
Only in the T24 and AY-27 cell lines, the treatment effects of PDT com-
bined with bleomycin were significantly higher than the sum of the 
single treatments. The heterogeneous response of the bladder can-
cer cell lines is probably a reflection of the heterogeneity of the dis-
ease. It is possible that the endocytosis and transport mechanisms 
of bleomycin or TPCS2a or both differ between the various cell lines. 
It has been well established that the cytotoxic effect of bleomycin 
varies widely between different tumours as well as between differ-
ent organs [17]. This might be due to differences in the cells’ DNA-re-
pair capacity, bleomycin hydrolase activity, cellular uptake mecha-
nisms, and possibly the rate of bleomycin efflux. In our experiments, 
TPCS2a represents an additional element. It is possible that different 
cell types use different endocytosis pathways leading to intracellu-
lar TPCS2a accumulation resulting in cell death without endosomal 
release. Another possible factor for the heterogeneous antiprolifer-
ative effects are the cellular resistance mechanisms to bleomycin. A 
better understanding of tumour biology and pathways critical for 
tumour genesis may provide personalized treatment opportunities 
for patients with urothelial cancer.
Conclusion
TPCS2a-based PCI of bleomycin showed a significant, at least, addi-
tive antiproliferative activity against human and rat UC cells in 
vitro. Therefore, PCI may have therapeutic potential as an intraves-
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ical strategy against NMIBC, provided patient stratification can be 
achieved based on a predictive biomarker (panel). Further studies 
are needed to explore whether such predictive biomarkers can be 
defined.
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Abstract
Bladder cancer is a major public health problem. Currently availa-
ble therapeutic options seem to be unable to prevent bladder cancer 
recurrence and progression. To enable preclinical testing of new in-
travesical therapeutic agents, a suitable bladder tumour model that 
resembles human disease is highly desirable. The aim of this topic 
paper was to discuss the problems associated with current in vivo 
animal bladder tumour models, focusing on the orthotopic synge-
neic rat bladder tumour model. In the second part of the paper the 
development of a potential new orthotopic rat bladder tumour mod-
el is described.
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Introduction
Bladder cancer is one of the most common malignancies with ap-
proximately 357,000 new cases (273,858 males and 82,699 females) 
worldwide in 2002 [1]. More than 90% of the bladder cancers are 
urothelial cell carcinomas (UCC) [2] and the majority (75-85%) pre-
sents initially as non-muscle invasive bladder cancer (NMIBC) [3]. Of 
these patients, about 70% presents with papillary lesions that are 
non-invasive and limited to the mucosa (Ta), 20% with lesions that 
invade the subepithelial connective tissue (T1) and 10% with carcino-
ma in situ (CIS). Transurethral resection of the bladder tumour (TUR-
BT), followed by adjuvant intravesical instillations with chemother-
apy and/or immunotherapy are considered standard treatment for 
NMIBC. In general, the probabilities of recurrence and progression in 
NMIBC at 5 years range from 31 to 78% and from less than 1% to 45% 
depending on grade and stage, respectively [4]. These rates illustrate 
the modest success of currently available treatments and underline 
the need for improved adjuvant treatment.
Although in vitro models are useful for initial development and 
evaluation of therapeutic agents and modalities, adequate animal 
models are still essential in the preclinical development of new ef-
fective and safe therapies for many human malignancies. It allows 
the investigation of aspects that cannot be studied under clinical 
conditions such as pharmacokinetics and toxicity. For bladder can-
cer in particular, much effort has been devoted to the development 
of an appropriate tumour model for the evaluation of new chemo-
therapeutic or immunotherapeutic agents, drug regiments, or other 
anti-tumour modalities.
The ideal animal bladder tumour model that resembles human dis-
ease both histologically and in behaviour should include the follow-
ing characteristics [5]:
1.  The tumour should grow intravesically (orthotopically), such that 
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the tumour can be directly exposed to intravesical anti-tumour 
drugs in its natural environment.
2.  The tumour should be of pure UCC origin, with different stages 
of disease progression (CIS, papillary and invasive diseases) and, 
as for the human disease, the majority of the tumours should be 
non-muscle invasive, but not progressive.
3.  The animal host should be immunocompetent and reasonably 
large, so it can be treated by various anti-tumour modalities such 
as immunotherapy with bacillus Calmette–Guérin (BCG), chemo-
therapy, and whole bladder photodynamic therapy (PDT).
4.  The tumour should be technically easy to develop within a rea-
sonable time period, and highly reproducible with respect to its 
natural history.
In this topic paper, we discuss existing in vivo rat bladder tumour 
models with their specific shortcomings. In the second part of the 
paper, we describe the development of a potential new orthotopic 
rat bladder tumour model.
Existing in vivo models
Rats and mice are the most common species used for in vivo UCC 
models. Rodents have a lower urinary tract comparable to humans 
and neoplasms in the bladder are morphologically very alike [6]. 
Bladder tumours in rodents can be established subcutaneously (het-
erotopically) or in the bladder (orthotopically) either by transplanta-
tion of tumour cells or by chemical induction.
Although murine orthotopic models are available [e.g. 7,8,9], these 
models are limited by the size of the animal, with a small urethral 
caliber, thin bladder wall and small bladder capacity as a conse-
quence. Catheterization of mice to introduce tumour cells, intra-
vesical therapeutics or for example an ultrathin cystoscope is more 
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difficult than in rats. A rat bladder is approximately 10 times larg-
er than the bladder of a mouse and the better developed muscular 
layer allows better histological assessment of depth of invasion and 
decreases the risk of perforation during bladder catheterization [10]. 
Therefore, in important aspects the rat model offers significant ad-
vantages over the murine model and in this topic paper only the rat 
model is further discussed.
Subcutaneous models
In rodent heterotopic UCC models, the tumour is usually located in 
the flank or hind leg of the animal. To establish a syngeneic sub-
cutaneous model for immunological studies, rodent UCC tumour 
fragments or cells are inoculated through a small incision into the 
immunocompetent host of the same strain from which the tumour 
was originally derived [11,12]. For a xenograft model human UCC 
fragments or cells are used. Subcutaneous tumours can be evaluated 
non-invasively by palpation or with the help of imaging techniques. 
Treatment can be administered by local injection or systemically.
Subcutaneous bladder tumour models have been widely used be-
cause of the ease of assessing tumour growth kinetics and because 
the orthotopic model is technically more difficult (see below) [13,14]. 
However, the microenvironment at the implantation site of the host 
organ can influence the natural history of tumour growth and the 
efficacy of anti-proliferative agents. In one study, for example [15], 
human colon carcinoma cells were implanted into different ana-
tomical locations (subcutaneous and cecum) of nude mice. Tumour 
bearing mice were treated with doxorubicin and subsequently eval-
uated for responses. The heterotopic subcutaneous tumours showed 
an 80% inhibition of growth, compared with 40% inhibition of the 
orthotopic intracecal tumours. The environment of the orthotopic 
model resembles that of naturally occurring tumours, so experimen-
tal results in this model would be expected to have more relevance 
than results in the subcutaneous model. In addition, heterotopic 
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grafts are unsuited to evaluate intravesical therapies and orthotopic 
models are thus to be preferred.
Orthotopic models: tumour development
To test potential new drugs against NMIBC in a preclinical setting, a 
clinically relevant rodent orthotopic bladder tumour model is highly 
desirable. Currently, there are three different kinds of orthotopic rat 
bladder tumour models: chemically induced bladder cancer mod-
els [16], the xenograft model (transplantation of human UCC into 
immunodeficient nude rats) [10] and the syngeneic tumour model 
(transplantation of carcinogen-induced bladder cancer in syngeneic 
immunocompetent rats) [5].
Given the importance of chemicals in the carcinogenesis of blad-
der cancer, organo-specific bladder carcinogens were discovered 
for rodents. These chemicals provided readily available reproduc-
ible models necessary for detailed studies of the pathogenesis of 
bladder cancer [17]. Three chemicals have been reported as being 
particularly effective in causing bladder tumours under the ap-
propriate conditions: FANFT (N-[4-(5-nitro-2-furyl)-2-thiazolyl]for-
mamide), OH-BBN (N-butyl-N-(4-hydroxybutyl)-nitrosamine) and 
MNU (N-methyl-N-nitrosurea) [18,19]. However, the use of chemicals 
to induce tumours in the rat bladder is time-consuming (several 
months) and there is a high amount of squamous differentiation. 
Furthermore, reproducibility is hampered by the variation in time 
to tumour development. Therefore, these models are less practical in 
therapeutic efficacy studies of novel anti-proliferative compounds.
Bladder tumour transplantation is a much faster approach to create 
a therapeutic in vivo orthotopic UCC model. Orthotopic xenografts 
in immunodeficient nude rats are useful in order to better approxi-
mate human tumour cell behaviour in situ, but are unsuited to test 
intravesical immunotherapy with for example BCG and are not fre-
quently used.
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Xiao et al. [5] described a syngeneic orthotopic rat model resembling 
human UCC, with reproducible tumour growth. The rat bladder UCC 
cell line AY-27 was established as a primary bladder tumour in Fis-
cher F344 rats by feeding FANFT. This rat bladder UCC cell line was 
transplanted orthotopically into female Fischer F344 rats. AY-27 UCC 
cells were grown in monolayer cell culture and instilled intravesi-
cally as single cell suspensions into bladders that had been precon-
ditioned with mild acid washing. In 82 animals sacrificed at 16 days, 
80/82 (97%) developed UCC, and in 52/80 (65%) the tumour was 
non-muscle invasive (CIS, T1, but no Ta). Histological examination of 
the tumour specimens confirmed the presence of grade II-III UCC. 
Immunocytochemistry confirmed that the tumour model main-
tained the features of UCC.
A potential demerit in this frequently used model is the timing of 
intravesical therapy after tumour cell inoculation: in some rats tu-
mours had not formed yet, while other rats already developed mus-
cle invasive tumours. Therefore, Hendricksen et al. [20] assessed the 
growth of UCC in this model over time, aiming to have a maximum 
number of rats with NMIBC at a particular time and thus optimize 
the future starting point of experimental intravesical treatment. It 
was shown that in this model tumours were formed at 3-5 days and 
remained non-muscle invasive up to 5 days. From 6 days, tumours 
progressed to muscle-invasive disease in 40% of the rats. The ob-
served increase in tumour aggressiveness might be explained by 
more passages in vitro.
Another disadvantage of transplantable models is that tumours 
prove to be invasive carcinomas (≥ T1) from the start, without any 
Ta tumours (which is the most common stage in human NMIBC). 
This is related to the bladder preconditioning with urothelial abra-
sion rather than to the aggressiveness of the AY-27 cell line. It is quite 
possible that the basal membrane is disrupted, which causes rapid 
invasion of tumour cells into the underlying layers of the bladder. 
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However, tumour cells instilled into normal (non-conditioned) blad-
ders did not result in tumour establishment [5]. Different methods 
of tumour establishment in orthotopic models have been described, 
ranging from intravesical instillation of tumour cell suspension af-
ter chemical urothelial denudation with MNU or the combination of 
HCl and KOH leading to multifocal lesions, to mechanical urothelial 
lesioning such as cauterization [21]. Intraparietal injection of tumour 
cells resulted in intramuscular tumours only [22,23]. Horiguchi et al. 
[24] however, reported also promising success rates without bladder 
preconditioning. Thus, the model could possibly be improved by con-
trolling the urothelial abrasion: the lesion should be only superficial, 
affecting only one or two of the three cell layers of the rat bladder 
urothelium. On the other hand, if one assumes that tumour cell im-
plantation on the urothelium injured during TURBT is a major cause 
of bladder cancer recurrence in humans, bladder preconditioning 
would resemble the clinical situation in case the model is used to 
test immediate postoperative intravesical treatments.
Orthotopic models: tumour evaluation
For proper determination of treatment response, confirmation of 
successful orthotopic tumour implantation before starting treat-
ment is desirable. Otherwise one has to rely on former experiments 
and conjecture stage and tumour take. Since there is no accurate 
documentation of the presence or extent of tumour before thera-
py in this case, the validity of any conclusion on the efficacy of the 
experimental agents is difficult and large experimental groups are 
needed to reach enough power. If the autopsy specimen after treat-
ment contained no tumour one could not conclude whether com-
plete tumour regression was caused by therapy or whether tumour 
implantation had failed. Therefore, a placebo group should always 
be added in treatment efficacy experiments in case successful tu-
mour implantation before starting treatment could not be assessed. 
In any case, there is the disadvantage of consuming more animals, 
either due to larger treatment groups or to adding a placebo group.
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Precise quantification of bladder tumour lesions is also needed to as-
sess responses to intravesical instillation of therapeutic agents. Ac-
curate non-invasive in vivo assessment of established tumours in the 
orthotopic model is difficult, particularly for early stage non-muscle 
invasive tumours. Magnetic resonance imaging (MRI) has been re-
ported for this purpose [25, 26]. However, until now it could not offer 
an accurate diagnosis of small early lesions (< 1 mm in diameter) due 
to its spatial resolution. Furthermore, it is relatively complicated and 
has high costs. Intravesical ultrasonography was also reported [27], 
and provided a positive-predictive ratio of tumour stage up to 85%, 
however, without information on tumour location and appearance. 
Bioluminescence imaging has the potential to become a valuable 
tool for the early detection of tumour growth, although biolumines-
cence was only first detectable on day 4 after tumour cell implanta-
tion in recently published studies [28,29]. Ultrathin cystoscopy [30] 
is a reliable method in diagnosing tumour growth in an orthotop-
ic rat bladder tumour model, with a specificity and sensitivity of > 
90% [20]. Unfortunately, in our own experience, cystoscopy is sub-
optimal in the follow-up of tumours after intravesical treatment in 
this model. Most probably the rather short interval between intra-
vesical instillation and cystoscopy, necessary because of the fast tu-
mour development, hampers reliable cystoscopy. This lack of a reli-
able method to follow-up tumour development makes it difficult to 
study treatment outcomes without sacrificing the animals, because 
the histological examination of the bladder appears to remain the 
golden standard for the determination of tumour growth.
Potential new orthotopic ACI rat bladder tumour (RBT323) 
model
In the search for the ideal animal bladder cancer model, we are cur-
rently developing a new orthotopic ACI rat bladder tumour (RBT323) 
model. The RBT323 tumour is a non-carcinogen-induced tumour and 
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arose spontaneously in an ACI rat. In the past, this RBT323 tumour 
was used as a subcutaneous rat bladder tumour model in our lab-
oratory [31,32]. Histologically, the RBT323 tumour is a grade 2-3 pure 
urothelial cell tumour with no squamous cells and the RBT323 cell 
line closely resembles human non-muscle invasive UCC both pheno-
typically and cytogenetically [11].
The rather short treatment window of the frequently used synge-
neic orthotopic AY-27/Fischer F344 rat bladder tumour model ham-
pers its use in the evaluation of new treatments for NMIBC [5]. More-
over, it was recently shown that carcinogen-induced rodent bladder 
tumours have gene expression profiles more similar to those of hu-
man invasive than non-invasive tumours and thus would be a better 
experimental model for the former [33]. For these reasons, we antic-
ipated an orthotopic RBT323 tumour in the ACI rat to be an appro-
priate syngeneic model to study the anti-tumour effects of possible 
new treatments.
To accomplish this, a RBT323 rat bladder UCC cell line was established 
and transplanted orthotopically into syngeneic female ACI/SeqHSD 
rats (Harlan Spraque Inc., Indianapolis, Ind, USA). RBT323 UCC cells 
were grown in monolayer cell culture and instilled into precondi-
tioned (mild acid washing) rat bladders as single cell suspensions. 
Tumour growth was assessed by ultrathin cystoscopy (0,5 mm di-
ameter) and 24 days after instillation of tumour cells all rats were 
sacrificed and subjected to necropsy. Cystectomy was performed 
for histopathological examination. Overall in three out of the four 
rats tumour was established. All tumours were non-muscle inva-
sive (T1a-T1c) except one T2a tumour (2002 TNM staging system). 
No metastases were found. Unfortunately, all tumours were covered 
with normal urothelium (figure 1). Still, initial results of this new or-
thotopic rat bladder tumour model are promising, because after 24 
days most of the tumours seem to be non-muscle invasive with a 
reasonably long time window for the administration of study drugs, 
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as a consequence. Further studies are now being performed to look 
for the reproducibility and longitudinal behavior of the model. Addi-
tionally, a study is performed without bladder preconditioning, but 
with optimized other transplantation conditions, trying to establish 
Ta tumours.
Figure 1: RBT323 rat UCC T1a tumour, with overlying normal 
urothelium.
Conclusion
To enable efficacy testing of new potential chemotherapeutic or im-
munotherapeutic agents, an orthotopic syngeneic non-muscle inva-
sive UCC rat bladder tumour model would be ideal. However, espe-
cially tumour cell implantation methods and diagnostic procedures 
for the early detection of tumour growth, and follow-up monitoring 
still need to be refined.
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Abstract
Objective
Apaziquone used intravesically showed significant activity in phase 
I and II marker lesion studies in non-muscle invasive bladder cancer. 
The objective of this study was to assess anti-tumour activity and 
safety of 3 different formulations of intravesical apaziquone in an 
orthotopic rat bladder cancer model.
Animals, materials and methods
Female Fischer F344 rats were instilled with 1.5 × 106 AY-27 urothelial 
cell carcinoma cells and divided in 3 treatment groups (n = 10) and 
1 placebo group (n = 6). Intravesical treatment was administered for 
1 hour on days 2 and 5. Rats were treated with apaziquone in the 
formulation used in phase I/II clinical trials (group 1); apaziquone 
with an altered buffering capacity being used in phase III clinical 
trials (group 2), and apaziquone as in group 2, but without propyl-
ene glycol in the diluent (group 3). On days 5 and 14, the bladder wall 
was inspected by cystoscopy and evaluated for macroscopic tumour 
growth. After sacrificing the rats (day 14), cystectomy was performed 
and the bladders were investigated.
Results
There were no signs of any toxicity due to the study drug. On histo-
pathologic examination of the bladders 0, 1, and 2 tumours per group 
were found in group 1, 2, and 3, respectively. In the placebo-treated 
group, 60% of animals developed tumour, which is comparable to 
untreated animals.
Conclusions
Apaziquone showed an excellent anti-tumour activity. The effec-
tiveness of apaziquone in this orthotopic rat bladder tumour model 
corroborates the clinical observations and implies the validity of this 
model.
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Introduction
Bladder cancer is the fourth most common malignancy in men, 
with an estimated 68,810 new cases and 14,100 deaths in the USA 
in 2008 [1]. The majority of patients (around 70%) initially present 
with non-muscle invasive bladder cancer (NMIBC) [2]. Transurethral 
resection of the bladder tumour (TURBT), possibly followed by ad-
juvant intravesical instillations with chemotherapy and/or immu-
notherapy are standard treatment for patients with NMIBC. The 
probabilities of recurrence and progression in NMIBC at 5 years after 
standard treatment range from 31% to 78% and from less than 1% 
to 45% depending on grade and stage, respectively [3]. These rates 
illustrate the modest success of currently available treatments and 
underline the need for improved adjuvant treatment.
Apaziquone, 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-
4,7-dione)-prop-β-en-α-ol, is a synthetic bioreductive alkylating 
indoloquinone. As a pro-drug it generates cytotoxic species (semi-
quinone/hydroquinone) after enzymatic activation by the enzyme 
DT-diaphorase. Apaziquone has good anti-proliferative activity in 
vitro [4] but has only a modest anti-tumour activity in in vivo an-
imal models and also in human clinical trials when the drug was 
given intravenously [5-7]. The lack of activity was mainly attributed 
to the rapid clearance of the drug (plasma half-life < 10 minutes) and 
poor drug delivery to tumour cells. When apaziquone was admin-
istered by intravesical instillation, it showed impressive activity in 
phase I and phase II marker lesion studies in NMIBC [8,9]. Although 
the activity of apaziquone has been demonstrated in marker lesion 
studies, to date apaziquone has not been tested in orthotopic blad-
der cancer models.
Apaziquone stability in urine is best at pH 8.5, and the drug be-
comes progressively less stable as pH becomes more acidic [10,11], 
which might influence anti-tumour efficacy. Propylene glycol in the 
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diluent improves the solubility of apaziquone, but the presence of 
propylene glycol might also influence anti-tumour efficacy as it sig-
nificantly impairs the penetration of apaziquone [12]. The objective 
of the current study was to assess efficacy and safety of 3 different 
formulations of intravesically installed apaziquone with slightly dif-
ferent buffer compositions, to improve drug stability, and propylene 
glycol content in the diluent, to improve solubility, in an orthotopic 
rat bladder cancer model [13].
Animals, materials, and methods
Animals
Animal procedures were performed according to the protocol ap-
proved by the Institutional Animal Care and Use Committee (IACUC, 
Radboud University Nijmegen Medical Centre, The Netherlands) 
and in compliance with national and European regulations. A total 
of 36 female Fischer F344 rats (Charles River, L’Arbresle Cedex, France) 
weighing 154-189 g were housed in individual cages (Techniplast, 
Milan, Italy) with goldflakes bedding (SPPS, Frasne, France) and en-
vironmental enrichment, in a temperature controlled environment 
with a 12-hour light/dark cycle with free access to standard chow 
and water.
Tumour cell line
The AY-27 urothelial cell carcinoma cell line was established as a 
primary bladder tumour in FANFT (N-[4-(5-nitro-2-furyl)-2-thiazolyl]
formamide) fed Fischer F344 rats. Cells were grown as a monolay-
er culture in RPMI-1640 medium with L-glutamine, supplemented 
with 10% fetal bovine serum, 100 U/mL penicillin G, and 100 µg/mL 
streptomycin at 37°C in a humidified 95% air/5% carbon dioxide at-
mosphere.
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Tumour cell implantation
The instillation procedure was essentially performed as described 
by Xiao et al. [14], resulting in greater than 80% bladder tumour es-
tablishment [13]. Experimental procedures were performed under 
inhalation anaesthesia: isoflurane 2%-5% (induction) followed by 
isoflurane 2%, nitric oxide 0.5 L/min, and oxygen 1 L/min. Before each 
catheterization, enrofloxacin (5-10 mg/kg) was injected subcutane-
ously for antibacterial prophylaxis. The rat bladder was catheterized 
via the urethra with a 16-gauge (1.4 mm) plastic intravenous cannu-
la (BD Biosystems, Erembodegem-Aalst, Belgium) and drained. The 
bladder was preconditioned with a 15 s instillation of 0.4 mL 0.1 M hy-
drochloride (HCl) and neutralized by adding 0.4 mL 0.1 M potassium 
hydroxide (KOH) for 15 s. The bladder was then drained and flushed 
3 times with 0.8 mL 0.01 M phosphate-buffered saline (PBS). Imme-
diately after bladder conditioning, freshly harvested AY-27 cells (pas-
sage 38) (1.5 × 106 cells in 0.5 mL medium, time between cell harvest 
and bladder inoculation less than 2 hours) were instilled via the cath-
eter and left indwelling for 60 minutes. Leakage of the cell suspen-
sion around the catheter was carefully monitored. Every 15 minutes, 
rats were rotated 90° to facilitate full bladder wall exposure. The 
catheter was removed after 60 minutes and the rats were allowed to 
void spontaneously. The well-being of the animals was monitored on 
a daily basis, with special emphasis on haematuria and weight loss.
Test agents
Apaziquone and solvents were supplied by Spectrum Pharmaceuti-
cals, Inc. (Irvine, CA, USA). All lyophilized powders and solvents for re-
constitution were maintained in the dark at 4°C and prepared fresh 
prior to each instillation.
Experimental groups
Rats were randomly assigned into experimental groups. Assuming 
a cure rate of 67% (complete response rate in clinical phase II mark-
er lesion study [8]), a tumour yield after tumour cell implantation 
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> 80% (model evaluation [13]), α = 0.05 and a power of 80%, sample 
size of treatment groups was estimated 10 (possible drop outs tak-
en into account). Rats were intravesically treated 2 and 5 days after 
instillation of the tumour cells. Treatment consisted of (1) 0.05 mg 
apaziquone (formulation used in phase I/II clinical trials)/0.5 mL sol-
vent (group 1, n = 10), (2) 0.05 mg apaziquone (different buffering 
capacity, used in phase III clinical trials)/0.5 mL solvent (group 2, n 
= 10), (3) 0.05 mg apaziquone as in group 2, but without propylene 
glycol in the diluent/0.5 mL 5 mg/mL sodium bicarbonate (group 3, n 
= 10), and (4) 0.05 mg placebo/0.5 mL 0.9% saline (group 4, n = 6). The 
placebo used was identical to the placebo used in the apaziquone 
clinical trials, containing the red dye FD and C Red no. 40, to match 
the color of the reconstituted apaziquone solution. The solvent used 
in groups 1 and 2 contained 30% vol/vol propylene glycol. One rat in 
the placebo group died during anaesthesia on day 0 and was exclud-
ed from the study. One rat in group 2 also died during anaesthesia 
although on day 5, and one rat in group 3 was sacrificed on day 9 
because the humane endpoint was reached. These two rats died be-
fore reaching the end of the experiment, but after they received both 
treatments, and were therefore not excluded from the study.
Tumour assessment
Macroscopic tumour growth was assessed by cystoscopy on day 5 
(before bladder instillation) and day 14 (before necropsy). A fiber op-
tic needle arthroscope (Karl Storz, Tuttlingen, Germany) with 1.0 mm 
diameter, 6.5 cm length, and miniature-straight forward 0° telescope 
was used. The catheter functioned as sheath with an airtight rub-
ber plug connected to it. The cystoscope was inserted and the blad-
der distended with 0.8 mL of air. The bladder surface was inspected 
systematically, and images were recorded with the AIDA DVD (Karl 
Storz, Tuttlingen, Germany).
On day 14, all rats were sacrificed by carbon dioxide inhalation and 
subjected to necropsy. Cystectomy was performed for histopatho-
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logic examination. The bladders were fixed in 10% buffered forma-
lin. After lamination, bladders were embedded in paraffin, and tis-
sue sections of 5 µm were cut and stained with haematoxylin-eosin 
(HE). Two observers (CAHK, specialized uro-pathologist, and HCA) 
evaluated the number of tumours, tumour stage (2002 TNM staging 
system), and tumour grade (2004 WHO/ISUP and WHO 1973 classi-
fication). Inflammation in mucosa and submucosa was quantified 
as no reaction, mild, moderate, or severe reaction. When no tumour 
was visible on first examination, 2 more sections (each 0.5 mm deep-
er) were taken, stained, and evaluated.
Results
Animal well-being
Two rats of the initial 36 rats died during anaesthesia (one on day 
0, which was excluded from the study, and one on day 5, which was 
not excluded). A third rat had to be sacrificed prematurely because 
the humane endpoint was reached. The body weight of this rat de-
creased more than 10% and haematuria and a decrease in general 
well-being was observed. On necropsy, the left ureter was dilated, 
most probably due to oedema around the bladder neck and left ure-
teral orifice. Histologic examination of the bladder of this rat showed 
a severe inflammatory reaction in mucosa and submucosa, but no 
tumour was observed. Mild haematuria after catheterization was 
observed infrequently. There were no other signs of impaired animal 
well-being. There were no signs of any toxicity due to the study drug.
Cystoscopy/macroscopy
A large diversity of lesions was seen on cystoscopy on days 5 and 14, 
ranging from 1 or 2 small lesions to more than 5 small lesions (< 0.5 
mm) or even big lesions (> 0.5 mm) per animal. Stone formation was 
not observed. Figure 1A shows a rat bladder (group 3) with a clearly 
visible lesion (arrow). The corresponding cystoscopic appearance is 
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shown in figure 1B, and the histologic aspect of the tumour in figure 
1C. However, in 8/12 instances, cystoscopic bladder wall inspection 
revealed identical defects (i.e., > 5 small lesions or big lesions), which 
were not confirmed by histology (not shown). 
Figure 1A: Rat bladder after cystectomy opened in longitudinal direc-
tion, with clearly visible lesion (arrow) (group 3). The scale is in mil-
limeters. B: Cystoscopic picture of the same lesion (arrow). C: Micro-
scopic picture of the same lesion, a high grade pT2G3 tumour with 
adjacent normal urothelium (arrow), orginal magnification, ×2.5.
Histopathology
Normal rat bladder tissue consists of an epithelium of 3 cell layers 
overlying the submucosa and muscularis. In apaziquone treatment 
groups, scattered foci of atypical hyperplasia with urothelium of 6 
cell layers, moderate nuclear atypia, increased cellularity, increased 
nuclear/cytoplasmic ratio, apoptosis, and few mitotic figures were 
observed. The remaining urothelium consisted of 3 cell layers with 
scattered individual atypical cells with moderate/strong nuclear 
atypia and low nuclear/cytoplasmic ratio. This histologic appear-
ance is consistent with atypia due to chemotherapeutic instilla-
tions.
Inflammatory reactions in mucosa and submucosa were quantified 
as no reaction, mild, moderate, or severe reaction. In most of the an-
imals, no or only a mild inflammatory reaction was noticed. One rat 
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in group 1 showed a moderate reaction and 1 rat in group 3 showed 
a severe reaction; this rat had to be sacrificed prematurely on day 9 
(see above).
In table 1, the number of tumours per treatment group are present-
ed. The two rats that died before reaching the end of the experiment, 
but after they received 2 treatments, were included in the analysis. In 
case they were excluded, numbers only slightly alter (table 1). In 60% 
of the animals in the placebo group (group 4), histologic evidence of 
tumour growth was observed. Histologic examination of the blad-
ders from rats in treatment groups 1, 2, and 3 showed tumours in 0%, 
10%, and 20% of rats, respectively. An example of a high grade pT2G3 
tumour is shown in figure 1C. Statistical analysis (Fisher’s exact test) 
comparing group 1 with placebo showed that apaziquone treatment 
was highly effective (P = 0.022).
Table 1: Number of tumours per treatment group.
Group Total no. of 
rats
No. of rats
with  
tumour
No. of rats 
without 
tumour
P value vs. 
placebo
1 10 0 10 0.022
2 10(9)a 1 9(8) 0.077 
(0.095)
3 10(9)b 2 8(7) 0.251 
(0.266)
4 5c 3 2 Not  
applicable
a  One rat died during anaesthesia on day 5.
b  One rat was sacrificed on day 9 because the humane endpoint 
was reached, however no tumour was observed. In parenthesis, 
the numbers when both rats were not included in the analysis.
c  One rat died during anaesthesia on day 0 and was excluded from 
the study.
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Discussion
Apaziquone, a bioreductive alkylating indoloquinone, was original-
ly developed by The Netherlands Cancer Institute [15]. Based upon 
its favourable preclinical activity, apaziquone was selected for clin-
ical evaluation and formulated for intravenous administration [4]. 
However, no clinical responses were documented in the subsequent 
phase II clinical trials [6,7]. Most probably, the rapid elimination [5] 
and relatively poor penetration of the drug compromised drug de-
livery to tumours following systemic administration [16]. Thereaf-
ter, apaziquone was tested in the intravesical treatment of urinary 
bladder cancer, where rapid clearance does not occur [9]. Moreover, 
the relative stability in urine of the compound during prolonged 
contact [11] avoided the problems encountered in systemic drug de-
livery. Finally, its molecular weight (288.3 g/mol) prevents systemic 
absorption from the bladder. In a dose finding study Puri et al. de-
termined that 4 mg/40 mL of apaziquone was well tolerated and 
could safely be administered in the bladder in patients with NMIBC 
[9]. Subsequently, Van der Heijden et al. performed a phase II mark-
er lesion study on 46 patients with Ta-T1 G1-G2 NMIBC undergoing 
TURBT [8]. The histologically confirmed complete response 2 to 4 
weeks after the last (sixth) instillation was 67% (31/46 patients), and 
warranted further study. Currently, 3 clinical studies are ongoing: 
2 with a single immediate post-TURBT instillation of apaziquone 
for patients with Ta G1-G2 NMIBC, and 1 with a course of adjuvant 
apaziquone treatment for patients with high risk and BCG (bacillus 
Calmette-Guérin)-refractory NMIBC.
During clinical development of apaziquone, buffer composition of the 
formulation was slightly modified in order to get a better lyophilized 
product. Although these modifications were not expected to affect 
the anti-tumour activity of apaziquone, formal evidence was lacking, 
and it was therefore considered important to examine the activity of 
different formulations in an orthotopic bladder cancer model.
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The efficacy of intravesical chemotherapy depends to a large extent 
on drug delivery to tumour cells [17]. Inadequate drug delivery is 
partly the result of dilution by residual urine and continuous urine 
production during the treatment, and the inability of the drug to 
penetrate the deeper layers of the bladder. An additional variable is 
the effect of urinary pH on drug stability. In the present study, the 
treatment efficacy of the standard apaziquone formulation used in 
phase I/II clinical trials was compared with the apaziquone formu-
lation with altered buffering capacity used in phase III trials and 
with the former formulation without propylene glycol in the dilu-
ent used to reconstitute apaziquone. Propylene glycol in the diluent 
was added to improve the solubility of apaziquone, but as the pres-
ence of propylene glycol might also influence anti-tumour efficacy 
by significantly impairing the penetration of apaziquone [12], this 
formulation was also tested. The placebo solution used in a phase 
III clinical trial with apaziquone was used as control. All 3 intravesi-
cal apaziquone formulations showed excellent anti-tumour activity 
against the orthotopic rat urothelial cell carcinoma AY-27 compared 
with placebo. As anticipated, rats treated with the placebo material 
demonstrated no anti-tumour activity.
The mechanism of action of apaziquone involves reduction by ox-
idoreductases (particularly DT-diaphorase) and the outcome of ther-
apy is also influenced by oxygen tension. Rat DT-diaphorase (NQO1) 
is much more efficient at reducing various substrates than human 
DT-diaphorase and moreover at higher rates [18-20]. This may be a 
confounding factor of our study.
Intravesical administration of all 3 apaziquone formulations was 
not associated with any significant acute toxicities. With the excep-
tion of 1 animal that had a dilated left ureter, which was most likely 
not drug-related, the animals showed no signs of impaired animal 
well-being. Systemic toxicity due to the study drug was not observed. 
More than 90% of the animals showed no or minimal inflammatory 
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reaction as judged by histology. Only 2 rats showed a significant in-
flammatory reaction, which is not unexpected after catheterization 
and intravesical chemotherapeutic treatment.
Macroscopic tumour growth was assessed by cystoscopy before the 
second apaziquone bladder instillation and immediately before nec-
ropsy. Unfortunately, cystoscopy was of little value to evaluate tu-
mour growth: in only 4/12 bladders, which were scored positive by 
cystoscopy (i.e., > 5 small lesions or ≥ 1 big lesion) tumours were his-
tologically confirmed. Most probably, these false positive lesions rep-
resent reversible reactive oedematous lesions caused by the chemo-
therapeutic instillation, which also can be seen in the human setting 
when cystoscopy is done early after an intravesical instillation. This 
is corroborated by our observation that no discordance between cys-
toscopy and histology was seen in the placebo group. Unfortunately, 
cystoscopy is clearly suboptimal for the detection of tumours in this 
set-up. Most probably, the rather short interval between intravesi-
cal instillation and cystoscopy, necessary because of the fast tumour 
development, hampers reliable cystoscopy. This lack of a reliable 
method to follow-up tumour development makes it difficult to study 
treatment outcomes without sacrificing the animals. The histologic 
examination of the bladder appears to remain the golden standard 
for the determination of tumour establishment.
Conclusion
Apaziquone showed an excellent anti-tumour activity compared 
with placebo. The effectiveness of apaziquone in this orthotopic rat 
bladder tumour model implies the validity of this model, although 
cystoscopic follow-up of tumours in case of simultaneous intra-
vesical treatments in these rats appears to have limitations. These 
results also corroborate clinical observations and provide strong 
preclinical evidence for the use of apaziquone as adjuvant therapy 
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against non-muscle invasive urothelial carcinoma and support on-
going and future clinical trials.
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Abstract
Objective
We determined the effect of protodynamic therapy against bladder 
cancer cells in vitro and in vivo. We investigated cis-urocanic acid 
(cis-UCA) in rat bladder cancer cell cultures and in an orthotopic rat 
urothelial carcinoma model to assess its safety and anti-prolifera-
tive activity.
Animals, materials and methods
The rat bladder cancer cell line AY-27 was exposed to cis-urocanic 
acid (BioCis Pharma, Turku, Finland) at pH 6.5 or 7.4 for 2 hours. Cell 
viability was measured by colorimetric assay at 24 and 48 hours. For 
in vivo experiments AY-27 cells were instilled into the acid treated 
bladder of 17 rats. After 4, 7 and 10 days 14 rats were treated intraves-
ically with cis-urocanic acid 6% (weight per volume) or vehicle. Rats 
were sacrificed on day 12 and the bladders were dissected. Immuno-
histochemical staining was done to assess apoptosis (caspase-3) and 
cell proliferation (Ki-67) in vivo.
Results
Cis-urocanic acid caused dose dependent, pH dependent inhibition 
of AY-27 cell proliferation, showing the protodynamic action at con-
centrations of 0.5% and 1%. At higher cis-urocanic acid doses com-
plete cell death was observed. All tumours detected in animals treat-
ed with vehicle were muscle invasive (stage T2 or greater) but only 
43% of tumours were muscle invasive in the cis-urocanic acid treated 
group (P = 0.049). There was no difference in the percent of apoptot-
ic or proliferating tumour cells between treatment groups. No signs 
of toxicity were observed.
Conclusions
Cis-urocanic acid showed direct anti-proliferative activity against rat 
bladder cancer cells in vitro and anti-tumour effects in vivo. It may 
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have therapeutic potential as an intravesical agent for non-muscle 
invasive bladder cancer.
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Introduction
The recommended treatment approach for non-muscle invasive 
bladder cancer (NMIBC) is complete transurethral resection of the 
bladder tumour, followed by 1 chemotherapeutic instillation. In tu-
mours at intermediate and high risk for recurrence and/or progres-
sion adjuvant intravesical therapy is recommended [1]. However, the 
clinical effectiveness of current intravesical therapy is limited, and 
serious local and systemic adverse effects may occur [2]. Thus, new 
therapeutic options are urgently needed to decrease the toxicity and 
enhance the efficacy of intravesical treatments of NMIBC.
Protodynamic therapy is a recently introduced concept of can-
cer treatment involving the inhibition of cancer cell proliferation 
by intracellular acidification, leading to apoptosis and cell death. 
Cis-Urocanic acid (cis-UCA; (2Z)-3-(1H-imidazol-4-yl)-2-propenoic 
acid), a natural amino acid metabolite found in mammalian skin 
after exposure to ultraviolet radiation, acts as a protodynamic drug 
capable of transporting protons from the mildly acidic extracellu-
lar medium into the tumour cell cytosol [3,4]. In vitro cis-UCA treat-
ment showed a direct, permanent anti-proliferative effect in human 
bladder cancer cell lines in a pH dependent manner and it was su-
perior to 4 other anti-cancer agents studied at therapeutically rele-
vant concentrations to suppress cell proliferation [5]. Since cis-UCA 
is an endogenous compound with no known serious adverse effects, 
protodynamic therapy with cis-UCA is considered a promising new 
treatment approach for various malignancies. We assessed the safe-
ty and anti-tumour activity of repeat intravesical cis-UCA admin-
istration in the orthotopic Fischer/AY-27 rat bladder urothelial cell 
carcinoma model in vivo.
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Animals, materials and methods
The AY-27 urothelial cell carcinoma cell line was originally estab-
lished as a primary bladder tumour in Fischer F344 rats fed with 
FANFT (N-[4-(5-nitrofuran-2-yl)-1,3-thiazol-2-yl]formamide) [6]. Cells 
were grown as a monolayer culture in RPMI-1640 medium supple-
mented with 10% fetal bovine serum (Sigma-Aldrich®), L-glutamine, 
100 U/mL penicillin G and 100 µg/mL streptomycin (Invitrogen™) 
at 37°C in a humidified 95% air/5% CO2 atmosphere. Medium was 
replenished twice weekly. Cells were passaged using trypsin/ethyl-
enediaminetetraacetic acid (Invitrogen) when confluent.
Cis-UCA was dissolved directly in culture medium to an 8% (weight 
per volume) concentration. To maintain pH during the experiments 
medium was supplemented with 25 mM PIPES (Sigma-Aldrich). 
Thereafter pH was adjusted to pH 6.5 or 7.4 with NaOH. Stock solu-
tions were sterile filtered (0.22 µm) and diluted in the same medium 
with the same pH for use in assays. Solutions were freshly prepared 
on the day of use. Culture medium pH was not measured at the end 
of cell incubation experiments.
AY-27 cells were plated at 10,000 cells per well in 96-well flat bottom 
microtitration plates. They were incubated at 37°C for 24 hours be-
fore treatment in 100 µL culture medium at pH 6.5 and 7.4. Cells were 
then incubated with 0.5% to 4% cis-UCA in medium at pH 6.5 or 7.4 
for 2 hours, washed once and incubated for the next 24 and 48 hours 
in culture medium at the corresponding pH. Cytotoxic activity was 
determined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zoliumbromide; Sigma-Aldrich) assay with 30 µL MTT (5 mg/mL) in 
phosphate-buffered saline added to each well. Blue dye taken up by 
cells during 4 hours of incubation at 37°C was dissolved in dimethyl 
sulfoxide (100 µL per well). Optical density at 595 nm was read on an 
automated 3550 Microplate Reader (Bio-Rad®).
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Animal procedures were done after approval by the institutional 
animal care and use committee of Radboud University Nijmegen 
Medical Centre, Nijmegen, The Netherlands. Procedures were in 
compliance with national and European regulations. A total of 17 fe-
male Fischer F344 rats (Charles River, L’Arbresle, France) weighing 128 
to 158 g were housed in individual cages with gold flakes bedding 
and environmental enrichment in a temperature controlled envi-
ronment with a 12-hour light/dark cycle, and free access to standard 
chow and water.
The instillation procedure was done essentially as described by Xiao 
et al. [6] resulting in greater than 80% bladder tumour establish-
ment [7]. Experimental procedures were performed using inhalation 
anaesthesia. Before each catheterization enrofloxacin (5 to 10 mg/
kg) was injected subcutaneously for antibacterial prophylaxis. The 
rat bladder was catheterized via the urethra with a 16-gauge 1.4 mm 
plastic intravenous cannula (BD® Biosystems) and drained. The blad-
der was preconditioned with a 15-second instillation of 0.4 mL 0.1 M 
HCl and neutralized by 0.4 mL 0.1 M KOH for 15 seconds. The bladder 
was then drained and conditioned by flushing 3 times with 0.8 mL 
0.01 M phosphate buffered saline. Immediately after bladder condi-
tioning AY-27 cells from passage 38 (1.5 × 106 in 0.5 mL medium) har-
vested within 1 hour before inoculation were instilled in the bladder 
via a catheter and left indwelling for 60 minutes. Leakage of the cell 
suspension around the catheter was monitored. Rats were rotated 
90 degrees every 15 minutes to facilitate full bladder wall exposure 
to the cell suspension. The catheter was removed after 60 minutes 
and the rats were allowed to void spontaneously. Rat well-being was 
monitored daily with special emphasis on haematuria and weight 
loss.
Assuming a response rate of 70%, an 85% tumour yield after tu-
mour cell implantation (model evaluation [7]), α = 0.05 and a power 
of 80%, the sample size of the treatment groups was restricted to 7 
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subjects. Rats were randomly assigned to experimental groups. They 
were treated intravesically under inhalation anaesthesia with 6% 
cis-UCA or 0.9% NaCl (vehicle) solutions adjusted to pH 5.8 at 4, 7 and 
10 days after tumour cell implantation. The solution was retained 
in the bladder for 60 minutes by clamping the catheter. The rats 
underwent 90-degree position changes every 15 minutes. After 60 
minutes the catheter was removed and the rats were allowed to void 
spontaneously. On day 12 all 14 rats were sacrificed by CO2 inhalation 
and necropsy was done. Cystectomy was performed for histopatho-
logical examination. To monitor successful tumour establishment 
another 3 rats were sacrificed and cystectomy was done 4 days after 
tumour cell implantation.
Bladders were fixed in buffered 10% formalin. After lamination the 
bladders were embedded in paraffin. Tissue sections (5 µm) were 
cut and stained with haematoxylin and eosin. Two observers (spe-
cialized uropathologist CAHvdK and HCA) evaluated the number of 
tumours, tumour stage (2002 TNM staging system), tumour grade 
(2004 WHO/ISUP and WHO 1973 classifications) and maximum inva-
sion depth. Mucosal and submucosal inflammation was quantified 
as no reaction, or as mild, moderate or severe reaction.
Immunohistochemical staining was performed to assess cell apop-
tosis and proliferation in vivo using rabbit anti-cleaved caspase-3 
antibody (D175, Cell Signaling Technology®) and rabbit anti-Ki-67 
monoclonal antibody (SP6, Lab Vision/Neomarkers, Fremont, CA, 
USA). Briefly, formalin fixed paraffin embedded sections were depa-
raffinized and subjected to antigen retrieval in 0.01 M sodium citrate 
buffer, pH 6.0, by boiling in a microwave for 10 minutes. Endogenous 
peroxidase was quenched by incubation in 0.3% H2O2 in 40% meth-
anol for 30 minutes. After pre-incubation in 20% normal goat serum 
for 30 minutes the primary antibodies were applied at dilutions of 
1:1,000 (caspase-3) and 1:200 (Ki-67), and incubated at 4°C overnight. 
After incubation the slides were treated with biotinylated goat an-
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ti-rabbit IgG (H + L) at 1:500 for 30 minutes (Vector Laboratories, Burl-
ingame, CA, USA) and then with a Vectastain® ABC kit according to 
manufacturer instructions. Sections were developed with 3,3’-diam-
inobenzidine tetrahydrochloride according to manufacturer instruc-
tions (DAB Plus and PowerDAB, ImmunoVision, Brisbane, CA, USA) 
and counterstained with haematoxylin. Two observers (CAHvdK 
and HCA) evaluated the slides and estimated the overall percent of 
apoptotic and proliferative cancer cells.
The statistical significance of differences in viability data in vitro 
was calculated with the 2-way Student t test. Two-tailed P values for 
differences in tumour invasion and staging were calculated in 2 × 2 
contingency tables using the Fisher exact test with P < 0.05 consid-
ered statistically significant.
Results
Cis-UCA pulse treatment for 2 hours caused dose dependent inhibi-
tion of AY-27 cell proliferation (figure 1). At 48 hours after pulse treat-
ment the 0.5% concentration of cis-UCA produced a nonsignificant 
decrease in cell survival of 12% at pH 6.5 and 2% at pH 7.4. The pH 
6.5 medium decreased the number of viable cells in the absence of 
cis-UCA by 12% in comparison with the pH 7.4 medium (P = 0.016). 
Incubation with 1% cis-UCA resulted in a significant 39% and 29% 
decrease at pH 6.5 and 7.4 (P = 0.0036 and 0.0053, respectively, figure 
1). The protodynamic action of cis-UCA was shown by the observa-
tion that cell viability in vitro was decreased more at pH 6.5 than 
at 7.4 using 0.5% and 1% cis-UCA, although the difference was not 
statistically significant. The 2% to 4% cis-UCA doses caused complete 
cell death at each pH (P < 0.001; figure 1), which was already visible 1 
day after treatment (data not shown).
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Figure 1: Mean ± SD percent of viable AY-27 cells in quadruplicate 
wells according to corresponding pH control after cis-UCA pulse 
treatment. Cells were incubated with 0.5% to 4% cis-UCA, pH 6.5 or 
7.4, for 2 hours, washed and cultured at same pH without cis-UCA 
for 48 hours. w/v, weight per volume.
In the orthotopic urothelial cell carcinoma model, in which 14 rats 
were sacrificed 12 days after tumour cell implantation, a tumour was 
observed in all except 1 for a total tumour establishment of 93%. In 
the 13 rats with successful establishment the histologically deter-
mined mean maximum tumour invasion depth was 1.65 mm in the 
vehicle group vs 1.33 mm in the cis-UCA group (P = 0.42, figure 2). In 
all 3 control rats sacrificed 4 days after tumour cell implantation, i.e., 
before the start of instillation treatments in the remaining animals, 
histological evidence of tumour establishment was observed with a 
mean maximum invasion depth of 0.50 mm (figure 2).
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Figure 2: Mean + SD tumour invasion in F344/AY-27 bladder cancer 
model in vivo was evaluated histopathologically in bladders dissect-
ed 4 (control) and 12 (vehicle and cis-UCA) days after AY-27 tumour 
cell implantation in bladder of F344 rats with successful tumour es-
tablishment.
For further analysis the observed tumours were divided into 2 
groups (Ta-T1 and T2 or greater) according to histologically evalu-
ated tumour stage. In the 3 control rats without treatment the tu-
mours were stages T1a, T1c and T2a, respectively, 4 days after tumour 
cell implantation. All tumours (100%) observed in the vehicle group 
were muscle invasive (stage T2 or greater) but only 3 of 7 (43%) in the 
cis-UCA group were evaluated as stage T2 or greater (P = 0.049).
Bladder tissue evaluated for tumour cell apoptosis and proliferation 
showed 0% to 10% caspase-3 positive tumour cells and about 90% 
Ki-67 positive tumour cells per rat irrespective of treatment. We not-
ed no gradient of apoptotic cells from superficial to deeper cells.
The body weight of rats in each treatment group increased normally 
with a slight, temporary decrease 1 day after each anaesthesia. There 
were no signs of impaired well-being. After catheterization mild 
haematuria was noted rarely. No sign of toxicity due to the study 
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drug was observed. Bladder wall inflammatory reaction was antic-
ipated after frequent catheterization. However, no inflammation or 
only mild/moderate inflammation was noted in most animals in 
each group.
Discussion
The principal approach to NMIBC management is transurethral 
bladder tumour resection, followed by intravesical chemotherapy 
or immunotherapy with bacillus Calmette-Guérin [1]. Since current 
therapies are only partially effective, often with serious local and 
systemic adverse effects [2], novel treatment options are required for 
NMIBC to improve the overall treatment success rate and the toxic-
ity profile.
We present what is to our knowledge the first in vivo data on the 
anti-tumour potential of protodynamic therapy with cis-UCA for ex-
perimental urothelial cell carcinoma of the bladder. The treatment 
concept is based on intracellular acidification induced cell death by 
a weak acid that transports protons into the cytosol of tumour cells 
in a pH sensitive manner. A clear dose dependent decrease in the 
viability of cultured AY-27 rat urothelial cell carcinoma cells was ob-
served after pulse treatment with cis-UCA for 2 hours. Closely similar 
responses were reported in 2 human bladder cancer cell lines after a 
corresponding pulse treatment aimed at modeling the time needed 
for a clinical intravesical chemotherapy treatment [5].
The effect was more pronounced in the mildly acidic (pH 6.5) condi-
tions than in the neutral/alkaline (pH 7.4) medium, substantiating 
the protodynamic action. Lack of a major difference in viability be-
tween the 2 treatments (pH 6.5 and 7.4) may reflect the fact that the 
0.5% and 1% concentrations of cis-UCA are high enough to instantly 
cause a small decrease in the intracellular pH of tumour cells, also in 
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the pH 7.4 medium [4]. Also, spontaneous acidification of the pH 7.4 
medium in the course of a rather long incubation may further de-
crease the pH difference in the incubation media initially adjusted 
to pH 6.5 and 7.4 [3], producing a similar protodynamic effect. Mild 
acidification of medium alone affected cell viability but only to a 
small extent and similar to results in 2 human bladder cancer cell 
lines with dissimilar differentiation stages [5]. The dose-response 
curve was steep, showing that a threshold concentration of cis-UCA 
is needed to enable transport of a sufficient amount of protons un-
der mildly acidic conditions. After this threshold is attained the ef-
fect appears irreversible, leading to cell death.
The Fischer/AY-27 rat bladder cancer model is an orthotopic model 
of urothelial carcinoma [6] with the practical advantage of a fair-
ly short time needed for bladder tumour establishment with a 
high yield [7]. No complete tumour regression was observed after 
3, 1-hour intravesical treatment sessions with 6% cis-UCA adjusted 
to pH 5.8. However, we noted a significant difference in the tumour 
stage attained after cis-UCA treatments. Three control rats sacrificed 
4 days after tumour cell implantation already had well established 
tumours with even muscle invasive disease in 1. Since intravesical 
treatments were started only 4 days after tumour cell implantation, 
established tumours may already have been too far advanced for 
an optimal cis-UCA treatment effect. That is, even if superficial cells 
were effectively treated, invading cells would most probably have 
remained unscathed.
Immunohistochemical analysis revealed no enhanced tumour cell 
apoptosis in cis-UCA treated animals. However, the slightly reduced 
tumour thickness suggests that cis-UCA treatment resulted in tu-
mour cell kill, most likely at the bladder surface. Our failure to detect 
more apoptotic tumour cells in cis-UCA treated animals was most 
likely due to the 2-day period between cis-UCA treatment and blad-
der harvest. Also, our in vitro experiments suggest that tumour cells 
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are efficiently killed within 1 to 2 days. This period is probably suffi-
cient to clear the cells in apoptosis induced by cis-UCA, as recently 
reported [3], explaining our observation. This should be studied in 
future experiments of protodynamic therapy, for instance by evalu-
ation at earlier times after cis-UCA treatment.
For effective cancer therapy tumour specific cell kill is the desired 
outcome to minimize damage to normal tissue. Generally nutritional 
and metabolic conditions create a major difference between solid tu-
mours and normal tissue, particularly with respect to the extracellu-
lar microenvironment in the interstitial space of tumours, which be-
comes significantly more acidic than in normal tissue. Tumour cells 
maintain cytosolic pH at neutral or slightly alkaline levels while the 
extracellular microenvironment is acidified at the same time, usual-
ly to around pH 6.7 [8-10]. For anti-tumour activity the protodynamic 
therapy concept takes advantage of the transmembrane pH gradient 
in tumours to kill tumour cells. For tumour specificity the concept 
takes advantage of the inherent difference between extracellular pH 
in tumours and in normal tissue. As a weak organic acid, cis-UCA has 
favourable acid dissociation properties [11] to achieve enhanced pen-
etration through the plasma membrane [12] to transport and release 
protons (H+ ions) into the cytosol of tumour cells in a pH depend-
ent manner, resulting in significant intracellular acidification, which 
triggers apoptosis [3,4]. Since proton transport by this mechanism is 
not possible in normal tissue in the absence of a transmembrane pH 
gradient, selective tumour cell kill can be achieved [3-5,8,12].
It is anticipated that an absent protodynamic treatment effect in 
normal tissue would improve the local and systemic tolerability 
of cis-UCA. As suggested by prior preclinical experience [5], repeat 
intravesical administration of cis-UCA was not associated with any 
significant (acute) toxicity in this study. The rats showed no sign of 
impaired well-being and we noted no systemic toxicity due to the 
study drug.
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Conclusion
Cis-UCA showed significant direct anti-proliferative activity against 
rat bladder cancer cells in vitro. Although the number of animals 
treated was limited, signs of anti-tumour effects were observed and 
repeat instillations were well tolerated. Thus, cis-UCA may have ther-
apeutic potential as an intravesical agent against NMIBC. A phase I 
dose escalating study was initiated in patients with primary or re-
current NMIBC to test this premise.
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Abstract
Objective
To study the pharmacokinetic and toxicity profile of intravesically 
administered TMX-101, with its active ingredient R-837, a synthetic 
Toll-like receptor (TLR)-7 agonist, in a pig model.
Animals, materials and methods
TLR-7 expression was determined by immunohistochemistry in hu-
man and pig bladder tissue. Four groups of six pigs received a 1-h 
intravesical instillation with R-837 of different formulations. Phar-
macokinetic analysis was performed on plasma. Toxicity evaluation 
included monitoring the well-being of the animals, peripheral blood 
cell counts, and interleukin-6 and creatinine measurements. Urine 
was collected for R-837 measurement and dipstick analysis. In total, 
three pigs per group were sacrificed 24 h post-treatment, and the 
remaining animals were sacrificed after 1 week. Histopathological 
examination of the bladder wall was performed.
Results
TLR-7 was homogeneously expressed in human and pig urotheli-
um. R-837 and vehicle were well tolerated without deterioration in 
animal well-being. Systemic R-837 absorption was low. Mean max-
imum plasma concentration of R-837 differed depending on the 
formulation. Post-treatment, plasma levels were negligible at 24 h. 
Histopathological examination of the bladders did not show signifi-
cant abnormalities, apart from the intended inflammatory reaction 
in the R-837 treated groups.
Conclusions
Intravesically administered R-837 in pigs, which showed a similar 
TLR-7 distribution in bladder tissue as humans, is well tolerated and 
causes no bladder wall toxicity, and formulations with poloxamer 
and hydroxypropyl-β-cyclodextrin showed less systemic absorption.
108
Introduction
The incidence of non-muscle invasive urothelial carcinoma of the 
bladder is high [1] and the prevalence is even higher as a result of 
the high recurrence rate after primary transurethral resection. In 
patients at high risk of tumour recurrence and/or progression to 
muscle invasive disease, intravesical bacillus Calmette-Guérin (BCG) 
immunotherapy for at least 1 year is indicated [1]. However, BCG is 
only partially effective and serious local and systemic side effects 
may occur [2]. Therefore, the development of new intravesical treat-
ment options to lower tumour recurrence and the progression of 
non-muscle invasive bladder cancer remains essential.
TMX-101 is an optimized formulation of R-837, 1-(2-methylpro-
pyl)-1H-imidazo[4,5-c]quinolin-4-amine, a synthetic low-molecu-
lar-weight (240.3 g/mol) immune response modifier and the lead 
compound of the imidazoquinoline family (Toll-like receptor-7, TLR-
7, agonists). Activation of TLR-7 by R-837 leads to an intracellular sig-
nalling cascade (MyD88/NF-κB pathway), causing a potent anti-vi-
ral and anti-tumour immune response [3]. R-837 is effective and well 
tolerated as a topical agent (Aldara®; Graceway Pharmaceuticals, 
LLC, Bristol, TN, USA) for the treatment of various benign and malig-
nant skin lesions [4].
TLR-7 is also expressed in murine and human bladder cancer cell 
lines and imidazoquinolines have potent direct biological effects on 
urothelial cell carcinoma cells by decreasing cell viability and induc-
ing apoptosis and cytokine production [5]. The direct effects appear 
to be the result of c-Myc down-regulation and may synergize with 
the immunomodulating action of imidazoquinolines [6]. In addition, 
initial results obtained in an immune competent, orthotopic mouse 
model suggested the presence of anti-tumour effects in vivo [5,6]. 
Therefore, imidazoquinolines may have therapeutic potential as an 
intravesical agent for bladder cancer.
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To determine whether R-837 may be suitable for bladder cancer thera-
py, we studied TLR-7 expression in human bladder cancer and normal 
bladder tissue, followed by an animal study in which three different 
intravesical formulations of R-837 and a vehicle control were tested 
for both potential and risks. We studied animal well-being, pharma-
cokinetic properties, cytokine production and bladder wall histology.
Animals, materials and methods
Detection of TLR-7 expression
In total, 15 formalin-fixed, paraffin-embedded human bladder can-
cer specimens, six normal bladder specimens and 28 different nor-
mal human tissue specimens (other than bladder) were stained for 
TLR-7 by Mosaic Laboratories, LLC (Lake Forest, CA, USA). In addition, 
porcine bladder, tonsil, heart, liver, spleen and kidney tissue samples 
were tested. In short, after antigen retrieval (Mosaic Laboratories, 
LLC), tissue sections were blocked with protein block (Dako, Carpin-
teria, CA, USA) for 5 min followed by incubation with anti-TLR-7 anti-
body (GeneTex, Irvine, CA, USA) diluted in Dako Diluent (Dako) for 30 
min. Slides were rinsed in buffer followed by detection using the En-
vision+ Rabbit HRP detection reagent (Dako) for 30 min. Slides were 
rinsed and developed with 3,3’-diaminobenzidine (Dako), counter-
stained with haematoxylin and mounted.
The staining intensity of each specimen was judged relative to the 
intensity of a control slide containing an adjacent section stained 
with an irrelevant species- and isotype-matched antibody. Staining 
of the section labelled with the negative reagent control was con-
sidered ‘background’. Sections were scored as: 0, no staining relative 
to background; 1+, weak staining; 2+, moderate staining; 3+ strong 
staining. Total positive staining (the sum of all staining at 1+, 2+ and 
3+) was recorded for each specimen. The H-score was calculated 
based on the summation of the product of percent of cells stained at 
110
each intensity using the equation: (3 × % cells staining at 3+) + (2 × % 
cells staining at 2+) + (1 × % cells staining at 1+). The H-score values 
were in the range 0-300.
Pig model
Animal procedures were performed according to the protocol ap-
proved by the Institutional Animal Care and Use Committee (Rad-
boud University Nijmegen Medical Centre, the Netherlands) and in 
compliance with national and European regulations.
Female pigs (Dutch Landrace) were used for the present study be-
cause the urogenital tract of the pig closely resembles the human 
urogenital system. The shape of the penis and the preputial divertic-
ulum prevent transurethral catheterization of a male pig. The sows 
were housed in special swine stainless steel battery cages (Kezkhaff 
RVS, Ven-Zelderheide, the Netherlands) and fed with universal swine 
food (Havens Voeders, Maashees, the Netherlands). The pigs were di-
vided into four groups of six animals. Experimental procedures were 
performed under general anaesthesia. Premedication contained a 
mixture of 10 mg/kg ketamine and 0.5-1.0 mg/kg midazolam i.m. in 
one injection. Sedation maintenance was carried out by the same 
mixture in half the dosage every 45 min. The bladder was emptied 
before the start of treatment (via 12-F Foley catheter) and 50 mL of 
the study drug was instilled intravesically. Animals received a solu-
tion of R-837 0.5% dissolved in 0.1 M lactic acid (group 1); a solution 
of R-837 0.5% dissolved in 0.1 M lactic acid, poloxamer 407 16% as 
emulsifying agent and hydroxypropyl-β-cyclodextrin (HPBCD) 15% 
as stabilizing agent (group 2); a solution of R-837 0.5% dissolved in 0.1 
M lactic acid, poloxamer 407 16% and HPBCD 5% (group 3) or a vehi-
cle control (0.1 M lactic acid) (group 4). The stability of R-837 in all for-
mulations has been checked previously and showed no degradation 
of the test item. The catheter was clamped and the instillation fluid 
was retained in the bladder for 60 min, after which the bladder was 
emptied. The bladder was not rinsed after emptying.
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Blood samples for blood cell count and creatinine measurement 
were collected before instillation and 60 min, 24 h and 1 week (just 
before cystectomy) after the beginning of instillation. Blood sam-
ples for pharmacokinetic analysis and cytokine (interleukin-6, IL-6) 
measurement were collected before instillation of the study drug 
and 15, 30, 60, 120, 240 and 480 min after the beginning of drug in-
stillation and also just before cystectomy. Plasma was collected for 
pharmacokinetic and cytokine analyses, stored at -80°C, and shipped 
on dry ice for analysis.
The post-treatment evacuated bladder content and the evacuated 
urine just before necropsy were collected for analysis of R-837 con-
centration. Urine was frozen immediately and stored in plastic tubes 
at -80°C, and shipped on dry ice for R-837 determination. Dipstick 
urinalysis was performed on the evacuated pre- and post-treatment 
urine and on the urine collected just before necropsy. R-837 con-
centrations in plasma and urine were determined by CHIMAN s.r.l. 
(Rottofreno, Italy) by liquid chromatography-mass spectroscopy/
mass spectroscopy (LC-MSMS). This method has been validated pre-
viously for human urine samples in the range 2-5000 µg/mL R-837 
concentrations and was considered adequately accurate (mean ac-
curacy, 104.0%) and precise (mean relative SD, 1.7%). Plasma samples 
for IL-6 measurement were analyzed by Areta International s.r.l. 
(Gerenzano, Italy) using the Quantikine Porcine IL-6 (P6000; R&D 
Systems, Minneapolis, MN, USA) kit.
Body temperature was measured rectally before and 1, 8 and 24 h 
and 1 week after starting treatment. The well being of the animals 
was monitored by experienced staff using a selected list of possible 
signs and symptoms of toxicity before the experiment, just after the 
instillation and just before cystectomy. 
After treatment, three animals per group were sacrificed and cys-
tectomized at 24 h and the remaining animals underwent the same 
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procedure at 7 days. Material from the bladders was collected and 
processed for histology: bladder biopsies of 1 cm2 were taken from 
dome, trigone, right lateral wall and left lateral wall and transferred 
into 10% formalin in PBS. Material was embedded in paraffin, sec-
tioned, and stained with haematoxylin and eosin. The slides were 
evaluated for signs of inflammation and allergic reaction in submu-
cosa and mucosa. Microscopic abnormalities were classified as no 
reaction, mild, moderate or severe reaction.
Results
TLR-7 expression
TLR-7 expression of the 15 human bladder cancer specimens showed 
positive staining in all samples, with a mean (SD, range) of 90% (9%, 
70-100%). The most intense staining was nuclear membrane/peri-
nuclear and weaker cytoplasmic staining (figure 1A). The mean (SD, 
range) H-score was 127 (23, 90-165). Positive staining was also ob-
served in six normal bladder epithelia specimens, with a mean (SD, 
range) of 95% (8%, 80 to 100%). Mean (SD, range) H-score was 179 (55, 
100-230). TLR-7 expression was observed in almost all non-bladder 
tissues examined (data not shown), most prominently in lymphoid 
tissue. A lack of staining was observed in heart and smooth muscle. 
TLR-7 expression in pig tissues (figure 1B) was similar to the corre-
sponding human tissues.
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Figure 1 A: Immunohistochemical staining for Toll-like receptor 
(TLR)-7 of human non-muscle invasive bladder cancer (original 
magnification, ×20). B: Immunohistochemical staining for TLR-7 of 
pig bladder (sub)mucosa (original magnification, ×40). C: Normal 
(sub)mucosal appearance of a pig bladder (haematoxylin and eosin, 
original magnification, ×20). D: Moderate predominantly lympho-
cytic submucosal inflammatory reaction 1 day after instillation of 
study drug (group 3) (haematoxylin and eosin, original magnifica-
tion, ×20).
Pig experiment
A total of 24 pigs with a mean (range) weight of 57.1 (40.0-85.0) kg 
were divided into four groups of six pigs treated with various formu-
lations of R-837 as a single 60-min intravesical instillation. Through-
out the 1-week follow-up period after instillation (three pigs per 
group), no deterioration of animal well-being was observed. Minor 
signs of toxicity possibly as a result of the study drug were observed 
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in four pigs (i.e. low food intake in three pigs, groups 1, 2 and 4; loose 
stool in one pig, group 1). There were no other signs of impaired an-
imal well-being.
Post-treatment body temperature was not influenced by the instilla-
tion of the study drug and was comparable with pre-treatment body 
temperature for all treatment groups. A slight increase in creatinine 
levels was observed 1 week post-instillation in groups 1 and 2, with-
out obvious correlation with the treatment modalities.
Haematology values were within the normal range, with the ex-
ception of one pig in group 1, which showed abnormal haematology 
values (haemoglobin concentration, 2.5 mmol/L; haematocrit, 12%; 
thrombocyte count, 18 × 109/L; leukocyte count, 8.8 × 109/L at the end 
of the 60-min instillation period). However, 24 h post-treatment al-
most all haematological values for this animal were within the nor-
mal range, except for the thrombocyte count (53 × 109/L), which was 
within the normal range 1 week post-instillation.
Post-treatment urinalysis (60 min after beginning of instillation) 
showed high amounts of R-837 (table 1) for all treatment groups, ex-
cept for the vehicle control group. The amount of R-837 collected in 
the urine of animals in group 1 was almost twofold higher than that 
of animals in groups 2 and 3, although this was not significant (ANO-
VA: P = 0.096). After 24 h, R-837 levels were very low (< 5 µg/mL).
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Table 1: Total amount of intravesically administered R-837 and the 
total amount of R-837 in collected post-instillation urine for individ-
ual treatment groups.
Group Administered total 
amount R-837 (mg)
End treatment total 
amount R-837, mg 
(range) (%)
1 269 219 (23-320) (81.4)
2 258 133 (64-176) (51.5)
3 248 122 (46-219) (49.1)
4 0 0 (-) (Not applicable)
Pharmacokinetic analyses showed only little systemic absorption 
(figure 2 and table 2). The mean maximum plasma level of group 
1 was threefold higher than the mean maximum plasma level of 
groups 2 and 3 (overall analysis, ANOVA: P = 0.026) resulting in a 
twofold area under the curve. After 8 h, almost no R-837 (< 2.10 ng/
mL) could be detected in any pig plasma.
Figure 2: Pharmacokinetic plasma parameters of R-837 per treatment 
group.
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Table 2: Pharmacokinetic plasma parameters of R-837 per treat-
ment group; mean (SD).
Group Cmax (ng/mL) AUC (ng*h/mL) t½ (h)
1 45.17 (29.96) 96.75 (50.42) 1.18 (0.12)
2 16.23 (10.22) 45.67 (26.53) 1.58 (1.05)
3 17.00 (6.57) 56.65 (24.94) 1.90 (1.06)
4 0 (0) 0 (0) Not applicable
Cmax, Maximum concentration; AUC, area under the curve; t½, half-
life.
IL-6 cytokine levels were similar in all groups, including the vehicle 
control group, with maximum IL-6 levels reached 8 h after installa-
tion of the study drugs (data not shown).
Macroscopic examination of the resected bladders showed no abnor-
malities, except for some areas with a haemorrhagical appearance 
in the pigs sacrificed 24 h post-instillation of TMX-101 (groups 1-3), 
which was less apparent or absent in the pigs sacrificed after 7 days.
Microscopic examination of the resected bladders showed no differ-
ence between the four sampled regions. In most animals from the 
three treatment groups, a moderate, predominantly lymphocytic 
submucosal inflammatory reaction was seen 24 h after intravesi-
cal instillation (figure 1D), which decreased to mild inflammation in 
the pigs sacrificed after 7 days. Twenty-four hours post-instillation, 
lymphocytic vasculitis was observed in three pigs, and was equally 
divided over the three treatment arms. Moderate myositis was ob-
served in one pig in group 1. Mild reactive atypical bladder epitheli-
um was observed in almost all animals sacrificed after 24 h, which 
disappeared over time and was not visible in the animals sacrificed 
after 1 week. Erosion, submucosal oedema and bleeding were mild, 
and no allergic reaction was observed.
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Discussion
Transurethral bladder tumour resection and adjuvant intravesical 
immunotherapy with BCG is the standard treatment for high-grade 
non-muscle invasive bladder cancer. However, many patients show 
a recurrence of disease and the impact on disease progression is only 
limited [7] or even absent [8]. Moreover, BCG treatment can lead to 
serious local and systemic side effects [2]. Therefore, novel therapeu-
tic treatment options to improve the overall treatment success rates 
(possibly with a lower toxicity profile) for non-muscle invasive blad-
der cancers are urgently needed.
R-837, a member of the imidazoquinoline family, has shown efficacy 
against many tumour types [9]. The compound binds to TLR-7, in-
ducing the production and secretion of pro-inflammatory cytokines, 
which consecutively induce a profound tumour-specific cell-mediat-
ed immune response, quite similar to the proposed working mecha-
nism of BCG. In addition, R-837 can exert direct apoptotic effects on 
tumour cells, stimulate TLR-independent gene expression and inter-
fere with adenosine receptor signalling pathways [9].
R-837 is effective and well tolerated as a topical agent for the treat-
ment of various benign and malignant dermatological lesions. Local 
skin reactions are the most common side effects [10]. R-837 has also 
been studied as systemic treatment modality: weekly administra-
tion of high-dose oral R-837 was studied in a phase I trial in patients 
with cancer [11]. Dose-limiting side effects were influenza-like symp-
toms and mild lymphocytopaenia.
Bladder cancer may be an interesting target for R-837 treatment. In-
travesical administration of R-837 resembles the topical treatment of 
skin lesions with direct contact with malignant cells and direct cy-
totoxicity or apoptosis induced by R-837 independent of an immune 
response. Moreover, intravesical instillation avoids losses from first-
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pass metabolism and allows the therapeutic effect of a drug to be 
localized at the desirable site with minimal systemic side effects.
Experimental evidence that imidazoquinolines may indeed be ap-
propriate treatment modalities for bladder cancer was provided by 
Smith et al. [5]. These investigators showed that TLR-7 is expressed 
in murine and human bladder cancer cell lines and that imidazo-
quinoline has direct biological effects on these cell lines: cell viability 
was decreased and apoptosis and cytokine production was induced. 
In addition, initial results obtained in an immune competent, ortho-
topic mouse model suggested the presence of anti-tumour effects in 
vivo [5,6,12].
To investigate whether the target of R-837, TLR-7, is expressed in 
human bladder cancer, we evaluated TLR-7 expression in 15 speci-
mens. Positive staining was shown in all samples, with a mean of 
90%; however, there was some heterogeneity in intensity, leading to 
H-scores in the range 90-165.
To evaluate the pharmacokinetics and possible toxicity of R-837 in-
stallations, experiments in pigs were performed. TLR-7 expression in 
porcine and human bladder tissue samples was similar, corroborat-
ing the validity of the pig model. Moreover, the pig closely resembles 
the human urogenital tract, providing the most relevant informa-
tion in a pre-clinical setting. Three different intravesical solutions of 
R-837 and a vehicle control (lactic acid solution) were studied. None 
of the tested formulations affected the general well-being of pigs 
(e.g. as judged by mucosal appearance, behaviour or food/water in-
take).
Plasma analysis showed only slight systemic absorption of R-837 
after bladder instillation, regardless of the formulation used. High 
amounts of R-837 were recovered in post-instillation urine. Although 
post-treatment urine R-837 levels in animals treated with R-837 in a 
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simple lactic acid solution (group 1) were almost twofold higher than 
in animals treated with R-837 formulations with poloxamer and HP-
BCD (groups 2 and 3), this difference was not significant. Neverthe-
less, the mean maximum plasma level of R-837 in group 1 was three-
fold higher than in animals from groups 2 and 3 (P = 0.026), most 
likely as a result of the increased and prolonged bio-adhesiveness 
of the drug formulations with poloxamer and HPBCD to the bladder 
wall. However, this effect was short lived: after 8 h, almost no R-837 
could be detected in the pig plasma and, after 24 h, R-837 levels in the 
urine were very low, regardless of R-837 formulation. It is possible 
that drug formulations 2 and 3 lead to longer, sustained membrane 
levels of R-837.
Plasma IL-6 levels were similar in all groups, including the vehicle 
control group, with maximum values being reached 8 h after blad-
der instillation, most likely as a result of the stress reaction after gen-
eral anaesthesia and bladder catheterization, rather than immunos-
timulation by R-837. Moreover, plasma R-837 levels were too low to 
be considered as physiological relevant.
Histopathological examination of the bladder wall showed the in-
tended inflammatory reaction in the R-837 treated groups. Apart 
from this intended inflammatory reaction, no significant abnormal-
ities were observed. Only the vasculitis may represent some toxic 
reaction, albeit this was transient. No vasculitis was observed in the 
animals sacrificed on day 7. It is not possible to make meaningful 
intergroup comparisons with these small numbers per group; how-
ever, no major difference between the tested R-837 solutions was 
observed.
The present study specifically examined the toxicity of R-837 in dif-
ferent formulations and is an extension of the study by Hayashi et 
al. [12] who investigated formulations containing R-837 and different 
ratios of lactic acid, poloxamer and HPBCD in mice. In mice, formu-
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lations with poloxamer decreased the systemic absorption of R-837 
and significantly reduced systemic and local induction of keratino-
cyte-derived chemokine. The addition of HPBCD (to enhance stabil-
ity and solubility) reduced the systemic and local levels of tumour 
necrosis factor α and keratinocyte-derived chemokine. In the pres-
ent study, such differences were not observed. However, the effects 
in mice were only observed at higher dose ranges and, in the present 
study, R-837 was used at a lower concentration (0,5%) compared to 
that employed in the mice study (1%). Moreover, the different V/m2 
ratio between mouse and pig bladder causes an additional lower-
ing of possible systemic effects. Therefore, the failure to show any 
differences in toxicity between the groups in the present study was 
anticipated.
Conclusion
Intravesically administered R-837 in pigs is well tolerated, causes no 
bladder wall toxicity, and formulations with poloxamer and HPBCD 
stay longer in the bladder with less systemic absorption. The safety 
profile of intravesical R-837 appears to be favourable compared to 
that of current therapies such as BCG. Considering the very similar 
pharmacokinetic and safety characteristics of the formulations used 
in groups 2 and 3, further efficacy studies will be initiated with R-837 
0.5% in 0.1 M lactic acid, poloxamer 407 16% and HPBCD 5%.
Acknowledgments
We thank the personnel support and service of the Animal Laborato-
ry, Radboud University Nijmegen Medical Centre.
121Chapter 6  |  Pharmacokinetics and toxicity of intravesical TMX-101: A preclinical...
References
1. Babjuk M, Oosterlinck W, Sylvester R et al.; European Association 
of Urology (EAU). 
 EAU guidelines on non-muscle-invasive urothelial carcinoma of 
the bladder. Eur Urol 2008;54:303-314
2. Witjes JA, Palou J, Soloway M et al. 
 Clinical practice recommendations for the prevention and man-
agement of intravesical therapy-associated adverse events. Eur 
Urol Suppl 2008;7:667-674
3. Hemmi H, Kaisho T, Takeuchi O et al. 
 Small anti-viral compounds activate immune cells via the 
TLR7 MyD88-dependent signaling pathway. Nat Immunol 
2002;3:196-200
4. Tyring S, Conant M, Marini M et al. 
 Imiquimod; an international update on therapeutic uses in der-
matology. Int J Dermatol 2002;41:810-816
5. Smith EB, Schwartz M, Kawamoto H et al. 
 Antitumor effects of Imidazoquinolines in urothelial cell carcino-
ma of the bladder. J Urol 2007;177:2347-2351
6. Liu H, Schwartz MJ, Hwang DH et al. 
 Tumor growth inhibition by an imidazoquinoline is associated 
with c-Myc down–regulation in urothelial cell carcinoma. BJU Int 
2008;101:894-901
7. Sylvester FJ, Van der Meijden AP and Lamm DL. 
 Intravesical bacillus Calmette-Guerin reduces the risk of progres-
sion in patients with superficial bladder cancer: a meta-analy-
sis of the published results of randomized clinical trials. J Urol 
2002;168:1964-1970
8. Malmström PU, Sylvester RJ, Crawford ED et al. 
 An individual patient data meta-analysis of the long-term out-
come of randomized studies comparing intravesical mitomycin C 
versus bacillus Calmettte-Guérin for non-muscle-invasive blad-
der cancer. Eur Urol 2009;56(2):247-256
122
9. Schön MP and Schön M. 
 Imiquimod: mode of action. Br J Dermatol 2007;157:8-13
10. Geisse J, Caro I, Lindholm J et al. 
 Imiquimod 5% cream for the treatment of superficial basal cell 
carcinoma: results from two phase III, randomized, vehicle-con-
trolled studies. J Am Acad Dermatol 2004;50:722-733
11. Witt PL, Ritch PS, Reding D et al. 
 Phase I trial of an oral immunomodulator and interferon inducer 
in cancer patients. Cancer Res 1993;53:5176-5180
12. Hayashi T, Crain B, Corr M et al. 
 Intravesical Toll-like receptor 7 agonist R-837: optimization of its 
formulation in an orthotopic mouse model of bladder cancer. Int 
J Urol 2010;17:483-491
123Chapter 6  |  Pharmacokinetics and toxicity of intravesical TMX-101: A preclinical...
124
125
Chapter 7
Summary
126
127Chapter 7  |  Summary
Summary
Initial therapy of non-muscle invasive bladder cancer (NMIBC) is 
transurethral resection, followed by intravesical chemotherapeutic 
or immunotherapeutic therapy (chapter 1). However, a substantial 
percentage of treated patients still experience tumour recurrences 
or even progression to muscle invasive bladder cancer because of 
low compliance with guideline therapy advises, and despite the use 
of adjuvant intravesical instillations, even when it is used. Moreover, 
current intravesical therapy is not without toxicity, and serious local 
and systemic adverse effects may occur. Therefore, improved new 
intravesical treatment modalities are urgently needed to reduce tox-
icity and to enhance efficacy. In this thesis the preclinical testing of 
several potential new intravesical treatment modalities for NMIBC 
are described.
Photochemical internalization is a novel light-directed drug delivery 
system, using a photosensitizer specifically localized in the mem-
branes of endosomes. The release of endocytosed drugs into the cy-
tosol of the target cell is triggered by illumination. Results present-
ed in chapter 2 show that meso-tetraphenyl chlorin disulphonate 
(TPCS2a)-based photochemical internalization significantly potenti-
ates the antiproliferative activity of bleomycin against human and 
rat urothelial carcinoma cells in vitro. The observed treatment effect 
however was heterogeneous, which is probably a reflection of the 
heterogeneity of the disease. It is possible that the cellular resistance 
mechanisms to bleomycin, and the endocytosis and transport mech-
anisms of bleomycin and/or TPCS2a differ between the various cell 
lines. Therefore, photochemical internalization may have therapeutic 
potential as an intravesical strategy against NMIBC, provided predic-
tive patient stratification can be achieved, as discussed in chapter 8.
While in vitro bladder tumour models are useful for initial develop-
ment and evaluation of therapeutic agents and modalities, adequate 
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animal models are still essential in the preclinical development of 
new effective and safe therapies. In chapter 3 the problems associat-
ed with current in vivo animal bladder tumour models are discussed, 
focusing on the orthotopic syngeneic rat bladder tumour model. Es-
pecially the rather short treatment window of the frequently used 
AY-27/Fischer F344 model hampers its use in the evaluation of new 
treatments for NMIBC. In the second part of the chapter the devel-
opment of a potential new orthotopic rat bladder tumour model is 
described. The initial results of this RBT323/ACI rat model are prom-
ising, because after 24 days most of the tumours still seem to be 
non-muscle invasive providing a reasonably long time window for 
the administration of study drugs. However, especially tumour cell 
implantation methods still need to be refined, because all tumours 
were covered with normal urothelium and prove to be invasive carci-
nomas (≥ T1) from the start, without any Ta tumours. Also non-inva-
sive in vivo diagnostic procedures for the early detection of tumour 
growth, and follow-up monitoring remains difficult, particularly for 
early stage non-muscle invasive tumours.
In chapter 4 the results of an efficacy and safety study with different 
formulations of the relatively new drug apaziquone in the orthotop-
ic Fischer/AY-27 rat bladder cancer model are discussed. Apaziquone 
showed an excellent anti-tumour activity compared to placebo and 
there were no signs of any toxicity due to the study drug. The effective-
ness of apaziquone in this orthotopic rat bladder tumour model implies 
the validity of this model, although cystoscopic follow-up of tumours 
in case of simultaneous intravesical treatments in these rats appears 
to have limitations, as in 8/12 instances, cystoscopy revealed lesions 
which were not confirmed by histology. Most probably, these false pos-
itive lesions represent reversible reactive oedematous lesions caused 
by the chemotherapeutic instillation. The results also corroborate clin-
ical observations and provide strong preclinical evidence for the use of 
apaziquone as adjuvant therapy against non-muscle invasive urotheli-
al carcinoma and support ongoing and future clinical trials.
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Another promising novel concept for the treatment of bladder can-
cer is presented in chapter 5. Protodynamic therapy with cis-urocan-
ic acid (cis-UCA) comprises the inhibition of cancer cell proliferation 
by intracellular acidification leading to apoptosis and cell death. Re-
sults presented in this chapter show that cis-UCA has significant di-
rect anti-proliferative activity against rat bladder cancer cells in vit-
ro, as well as inhibitory effects on tumour growth in an orthotopic 
rat bladder cancer model in vivo. Additionally, the study showed that 
repeated intravesical instillations of cis-UCA in rats are well tolerat-
ed. Considering the efficacy and good side-effect profile of cis-UCA, it 
may play a role as an intravesical agent in the future.
R-837 is a Toll-like receptor (TLR)-7 agonist and the active ingredient 
of the promising new intravesical anti-bladder cancer drug TMX-101. 
Results presented in chapter 6 demonstrate that the distribution of 
TLR-7 in pig and human bladder tissue is similar and that TLR-7 is 
highly expressed in human bladder cancer. Furthermore, the results 
of a porcine pharmacokinetics and toxicity study of three different 
formulations of TMX-101 are presented. Intravesically administered 
R-837 in pigs is well tolerated, causes no bladder wall toxicity and 
formulations with poloxamer and hydroxypropyl-β-cyclodextrin 
stay longer in the bladder with less systemic absorption.
In conclusion, it is clear that current adjuvant intravesical treatment 
strategies against NMIBC are suboptimal and need to be improved. 
This thesis contributes in the continuous search for more effective 
and less toxic anti-cancer treatments by the preclinical testing of 
potential emerging intravesical treatment modalities. However, all 
treatment strategies described in this thesis need more (pre-)clini-
cal studies before they can really contribute in the treatment of pa-
tients with bladder cancer.
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Samenvatting
De initiële behandeling van niet-spierinvasief blaascarcinoom 
(NMIBC) is transurethrale resectie, gevolgd door intravesicale che-
mo- of immunotherapie (hoofdstuk 1). Helaas worden de behande-
lingsadviezen uit de richtlijnen slechts in beperkte mate gevolgd. 
Bovendien, zelfs wanneer de geadviseerde adjuvante intravesicale 
instillaties wel worden toegediend, dan ontwikkelt nog steeds een 
aanzienlijk percentage van de behandelde patiënten een tumorre-
cidief of zelfs progressie naar spierinvasieve blaaskanker. Daarnaast 
is het zo dat de huidige intravesicale behandelingen niet zonder 
toxiciteit zijn en er ernstige lokale en systemische bijwerkingen 
kunnen optreden. Nieuwe intravesicale behandelingen met minder 
toxiciteit en verbeterde effectiviteit zijn daarom dringend nodig. In 
dit proefschrift worden preklinische studies van enkele potentiële 
nieuwe intravesicale behandelingen voor NMIBC beschreven.
Fotochemische internalisatie is een nieuwe technologie voor licht-
gestuurde toediening van geneesmiddelen. Speciale fotosensibilisa-
tors accumuleren na toediening specifiek in de membraan van en-
dosomen. De fotosensibilisators worden vervolgens door belichting 
geactiveerd, waardoor de endosomale membraan wordt vernietigd. 
Geëndocyteerde geneesmidddelen komen zo vrij in het cytosol en 
kunnen hun intracellulaire doelwit bereiken. De in hoofdstuk 2 ge-
presenteerde resultaten laten zien dat fotochemische internalisatie 
met meso-tetrafenyl chlorine disulfonaat (TPCS2a) de antiprolifera-
tieve activiteit van bleomycine tegen humane en rat urotheelcarci-
noom cellen significant versterkt in vitro. Het waargenomen effect 
van de behandeling was echter heterogeen, hetgeen waarschijnlijk 
een reflectie is van de heterogeniteit van blaaskanker zelf. Het is mo-
gelijk dat de cellulaire afweer mechanismes tegen bleomycine en de 
endocytose- en/of transportmechanismes van bleomycine en/of 
TPCS2a verschillen tussen de verschillende cellijnen. Fotochemische 
internalisatie is daarom een potentiële intravesicale behandelstra-
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tegie tegen NMIBC, mits patiënten predictief kunnen worden ge-
stratificeerd, zoals wordt bediscussieerd in hoofdstuk 8.
In vitro blaastumor modellen zijn nuttig voor de initiële ontwikke-
ling en evaluatie van geneesmiddelen. Echter voor de preklinische 
ontwikkeling van nieuwe effectieve en veilige behandelingen zijn 
adequate diermodellen nog steeds essentieel. In hoofdstuk 3 wor-
den de problemen van de huidige in vivo blaastumor diermodellen 
besproken, de focus ligt daarbij op het orthotope syngene rat blaas-
tumor model. Het frequent gebruikte AY-27/Fischer F344 rat model 
wordt met name beperkt in zijn toepasbaarheid vanwege de rela-
tief korte periode waarin het geschikt is voor het testen van nieuwe 
behandelingen voor NMIBC. In het tweede deel van het hoofdstuk 
wordt de ontwikkeling van een potentieel nieuw orthotoop syn-
geen rat blaastumor model beschreven. De eerste resultaten van 
dit RBT323/ACI rat model zijn veelbelovend. Na 24 dagen lijkt het 
grootste deel van de tumoren nog steeds niet-spierinvasief te zijn, 
waardoor er een redelijk lange periode voor de toediening van stu-
die geneesmiddelen beschikbaar is. Met name de tumorcel implan-
tatie methoden moeten nog worden verfijnd, alle tumoren worden 
namelijk bedekt met normaal urotheel en bovendien zijn het inva-
sieve carcinomen (≥ T1) vanaf het begin, zonder een enkele Ta tumor. 
Daarnaast blijven niet-invasieve in vivo diagnostische procedures 
voor de vroege detectie van tumor groei en controle na behandeling 
moeilijk, met name voor niet-spierinvasieve tumoren in een vroeg 
stadium.
In hoofdstuk 4 worden de resultaten van een studie naar de effecti-
viteit en veiligheid van verschillende formuleringen van het relatief 
nieuwe geneesmiddel apaziquone in het orthotope Fischer/AY-27 
rat blaaskanker model besproken. Apaziquone vertoonde een uitste-
kende anti-tumor activiteit in vergelijking met placebo en er waren 
geen tekenen van toxiciteit die veroorzaakt werden door het studie-
geneesmiddel. De effectiviteit van apaziquone in dit orthotope rat 
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blaastumor model impliceert de validiteit van het model, hoewel 
de cystoscopische controle van tumoren in het geval van simultane 
intravesicale behandelingen beperkingen blijkt te hebben in deze 
ratten. In 8/12 gevallen toonde cystoscopie namelijk vals positieve 
laesies, welke meest waarschijnlijk reversibele reactieve oedema-
teuze laesies vertegenwoordigen, veroorzaakt door de chemothera-
peutische instillatie. De resultaten van deze studie bevestigen ook 
de klinische waarnemingen en leveren sterk preklinisch bewijs voor 
het gebruik van apaziquone als adjuvante therapie tegen NMIBC en 
ondersteunen lopende en toekomstige klinische studies.
Een ander veelbelovend nieuw concept voor de behandeling van 
blaaskanker is beschreven in hoofdstuk 5. Protodynamische be-
handeling met cis-urocaanzuur (cis-UCA) remt de proliferatie van 
kankercellen door intracellulaire aanzuring, hetgeen leidt tot apop-
tose en celdood. De in dit hoofdstuk gepresenteerde resultaten la-
ten zien dat cis-UCA significante directe antiproliferatieve activi-
teit tegen rat blaaskanker cellen in vitro heeft, en bovendien een 
remmend effect op de tumorgroei in een orthotoop rat blaaskanker 
model in vivo. Daarnaast liet de studie zien dat herhaalde intrave-
sicale instillaties van cis-UCA in ratten goed worden getolereerd. 
Gezien de werkzaamheid en het goede bijwerkingenprofiel van cis-
UCA, kan het een rol spelen als intravesicaal geneesmiddel in de 
toekomst.
R-837 is een TLR-7 agonist en het werkzame bestanddeel van het 
veelbelovende nieuwe intravesicale anti-blaaskanker geneesmiddel 
TMX-101. De in hoofdstuk 6 gepresenteerde resultaten tonen dat de 
distributie van TLR-7 in varkens- en humaan blaasweefsel vergelijk-
baar is en dat TLR-7 een hoge expressie kent in humaan blaaskanker-
weefsel. Verder worden de resultaten van een farmacokinetiek- en 
toxiciteitstudie in varkens gepresenteerd met drie verschillende for-
muleringen van TMX-101. Intravesicaal toegediend R-837 bij varkens 
wordt goed getolereerd, het veroorzaakt geen blaaswand toxiciteit 
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en formuleringen met poloxameer en hydroxypropyl-β-cyclodextri-
ne blijven langer in de blaas met minder systemische absorptie.
Concluderend is het duidelijk dat de huidige adjuvante intravesica-
le behandelingsstrategieën tegen NMIBC suboptimaal zijn en dus 
moeten worden verbeterd. Dit proefschrift draagt bij aan de conti-
nue zoektocht naar efficiëntere en minder toxische anti-kanker be-
handelingen door middel van preklinische studies van potentiële 
intravesicale behandelingen in opkomst. Echter alle behandelings-
strategieën beschreven in dit proefschrift hebben meer (pre-) klini-
sche studies nodig voordat ze echt een bijdrage kunnen leveren aan 
de behandeling van patiënten met blaaskanker.
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Future perspectives
Urinary bladder cancer poses a considerable burden on both patients 
and health care systems. 2.40% of men and women born today will 
be diagnosed with bladder cancer during their lifetime [1], and, per 
patient, bladder cancer is the most expensive cancer [2]. The stand-
ard initial therapy for non-muscle invasive bladder cancer (NMIBC) 
is complete macroscopic transurethral resection (TURBT) followed by 
intravesical therapy [3]. However, compliance with guidelines is low, 
tumour recurrence is frequent and some tumours are progressing to 
muscle invasive disease, underscoring the suboptimal clinical outcome 
of current treatment. Furthermore, current treatment is not without 
toxicity. This thesis contributes to the continuous scientific pursuit for 
better therapeutic options through the preclinical testing of new in-
travesical treatments against NMIBC. Four different treatment modal-
ities are discussed, i.e., photochemical internalization, chemotherapy, 
protodynamic therapy, and immunotherapy, respectively.
For the preclinical development of new effective and safe intravesi-
cal therapies animal models are still essential. However, new regen-
erative medicine and tissue engineering techniques may offer new 
possibilities for the replacement of animal models. Janssen et al. [4] 
recently developed an ex vivo organoid bladder mucosa model using 
organotypic culturing for advancing preclinical research of the blad-
der and to generate alternatives for currently used in vivo models. 
This kind of in vitro and ex vivo models may support pharmacolo-
gy and toxicology research to develop new anti-cancer treatments. 
These models could be used as an alternative for animal experiments 
and, furthermore, therefore accelerate the preclinical research phase 
in pharmacological development.
TPCS2a-based photochemical internalization (PCI) of bleomycin 
may have therapeutic potential as an intravesical strategy against 
NMIBC. However, the observed treatment effect in vitro was heter-
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ogeneous, and, as for most anti-cancer treatments, a stratification 
to predict treatment responses would be highly desirable. A better 
understanding of tumour biology and pathways critical for tumour 
genesis may provide personalized treatment opportunities for pa-
tients with urothelial cancer, as will be discussed below. Further-
more, preclinical animal studies should be performed to substan-
tiate the value of PCI following our in vitro study. For example, a 
logical next step in the development would be an efficacy study in 
an orthotopic rat bladder tumour model with 4 treatment groups, 
i.e., control, bleomycin, TPCS2a-based photodynamic therapy, and 
TPCS2a-based PCI of bleomycin. A phase I/II study of TPCS2a-based 
PCI of bleomycin in locally recurrent or advanced/metastatic, (sub)
cutaneous malignancies showed no unexpected side effects [5]. Pre-
liminary efficacy data were also very encouraging and a phase II 
study to evaluate the safety and efficacy of TPCS2a in combination 
with bleomycin with laser light application in patients with recur-
rent head and neck squamous cell carcinoma has recently been initi-
ated [6]. Provided that it shows positive results, this trial might pave 
the way for future trials in NMIBC.
Intravesical chemotherapy with apaziquone is a very promising 
future treatment modality against NMIBC. Apaziquone showed a 
complete response of 67% (31/46 patients) in a phase II marker le-
sion study on 46 patients with TaT1 G1-2 NMIBC undergoing TURBT 
[7] as already discussed in chapter 4. Hendricksen et al. [8] showed 
that the long-term results of apaziquone treatment are favourable 
in comparison to the results of other ablative studies: the complete 
response was followed by a recurrence-free rate of 56.5% at 1-year 
follow-up, and 49.5% at 2-year follow-up. A phase II study in inter-
mediate- and high-risk NMIBC patients treated with adjuvant intra-
vesical instillations of apaziquone, showed a recurrence in 34.7% of 
patients after 12 months and 44.9% after 18 months. Only 1 of 53 pa-
tients (1.9%) had progression. The instillations were in general well 
tolerated and the results can be considered promising [9].
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Currently, we are waiting for the official publication of the results 
of two large placebo controlled phase III clinical trials with a sin-
gle immediate post-TURBT instillation of apaziquone for patients 
with Ta G1-2 NMIBC [10,11]. Another study with a single immedi-
ate post-TURBT instillation of apaziquone for patients with Ta G1-2 
NMIBC is still ongoing in Japan and Korea [12]. Spectrum Pharma-
ceuticals, Inc. (Irvine, CA, USA) already announced in a press release 
that both phase III trials did not meet their primary endpoint of a 
statistically significant difference in the rate of tumour recurrence 
at 2 years between the two arms. However, analysis of the pooled 
data from both studies showed a statistically significant treatment 
effect in favour of apaziquone in the primary endpoint of the rate 
of tumour recurrence at 2 years (P = 0.0174) and in a key secondary 
endpoint, time to recurrence (P = 0.0076) [13]. However, in both stud-
ies, patients at intermediate risk of recurrence with multiple (up to 
4) and recurrent tumours were also included. Gudjónsson et al. [14] 
showed that a single, early instillation of epirubicin after TURBT 
prevents tumour recurrences, mainly in cases of primary, solitary 
tumours and that such treatment was not beneficial in patients at 
intermediate- or high-risk of recurrence. Therefore, a subgroup anal-
ysis for patients at low-risk of recurrence (i.e., primary, solitary, Ta, G1 
tumours) would be interesting in both phase III trials.
Two large international phase III multicenter randomized trials eval-
uating the efficacy and safety of multiple instillations of intravesical 
apaziquone versus placebo in patients with low-intermediate risk 
NMIBC are ongoing with preliminary data collection to be complet-
ed by year end 2014 [15,16].
It can be concluded that apaziquone is a very promising intravesical 
agent for the treatment of NMIBC, its potency and relatively low 
toxicity have been clearly demonstrated by in vitro and in vivo pre-
clinical studies, and subsequent phase I and II clinical trials. Howev-
er, (more) phase III studies are urgently needed before apaziquone 
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can be positioned as one of the new standards of treatment in pa-
tients with NMIBC. The results of our preclinical efficacy and safety 
study with different formulations of apaziquone corroborate the 
clinical observations so far, and support ongoing and future clinical 
trials.
Protodynamic therapy with cis-urocanic acid (cis-UCA) is another 
promising novel concept for the treatment of bladder cancer. Con-
sidering the efficacy and good side-effect profile of cis-UCA observed 
in our study, it may play a role as an intravesical agent in the fu-
ture. A phase I study with intravesical cis-urocanic acid to evaluate 
its safety, tolerability and pharmacokinetics in patients with prima-
ry or recurrent non-muscle invasive bladder cancer [17] has recently 
been completed in Finland and we are waiting for the results to be 
published.
Another potential new intravesical anti-bladder cancer treatment 
modality is immunotherapy with TMX-101, a Toll-like receptor (TLR)-
7 agonist. Our porcine pharmacokinetics and toxicity study of three 
different intravesical formulations of TMX-101 was followed by a 
phase I study by Falke et al. [18]. This study confirmed the clinical 
safety of six intravesical instillations with TMX-101. In total, 88 in-
stillations were administered in 16 patients. There was limited dose 
dependent systemic uptake. The reported side-effects were mild or 
moderate, mostly local and resolved without intervention. No dose 
dependant increase in frequency or severity of the adverse events 
was observed. Currently, a marker lesion study is ongoing in 4 Dutch 
hospitals to investigate the efficacy of TMX-101 as intravesical treat-
ment for NMIBC patients [19]. Furthermore, there is ongoing pre-
clinical work on a second generation compound, TMX-202. This is 
a highly specific and potent TLR-7 agonist with a higher molecular 
mass than TMX-101 and, therefore possible less systemic uptake [20], 
which might be favourable.
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Although this thesis focuses on the development of new intravesical 
treatment modalities for NMIBC, other aspects are also of great im-
portance to improve future treatment of NMIBC. First of all, to reach 
future goals in bladder cancer treatment, it is of utmost importance 
to increase bladder cancer research funding. Carter et al. [21] recent-
ly revealed that bladder cancer has the lowest research funding per 
clinical case of all cancers. A considerable mismatch between fund-
ing levels and burden was shown. Some cancers are funded at lev-
els far higher than their relative burden suggests, while others (e.g., 
bladder cancer) appear very much underfunded.
TURBT is a crucial initial procedure in the treatment of NMBC and 
a complete and correctly performed TURBT is essential to achieve 
a good prognosis [22]. Training in TURBT is important: it has been 
shown that surgical experience can improve TURBT results [23]. 
Moreover, more complete tumour resection can be achieved 
with new methods of tumour visualization like hexaminolevuli-
nate-guided photodynamic diagnosis (PDD) [24]. If the initial TURBT 
is optimal, a re-resection could possibly be avoided and the need for 
a single immediate postoperative instillation reduced. Furthermore, 
if areas with CIS could be resected completely with the help of PDD 
or other future techniques, the outcome and prognosis of patients 
with CIS would hopefully improve. 
A major problem in NMIBC management is the suboptimal adher-
ence to evidence based guideline recommendations. Chamie et al. 
[25] retrospectively analyzed 4,545 subjects diagnosed with high-
grade NMIBC between 1992 and 2002 who survived at least 2 years 
without undergoing definitive treatment and found only 1 case of 
comprehensive compliance. Approximately 42% of physicians have 
not performed at least 1 cystoscopy, 1 cytology, and 1 instillation of 
immunotherapy for a single patient within their practice during the 
initial 2-year period after diagnosis. Physician-attributable variation 
for individual guideline measures (cystoscopy, 25%; cytology, 59%; 
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intravesical chemotherapy, 45%; and intravesical immunotherapy, 
26%) contributed to this low compliance rate. This study clearly il-
lustrates the urgent need for strategies to improve guideline compli-
ance. First of all, it is critical to identify the barriers for proper guide-
line compliance. Potential barriers are concerns about side-effects, 
lack of knowledge about guideline recommendations, and unaware-
ness of the importance of adherence to evidence based guidelines. 
Effective communication between patient and physician, and edu-
cation of patient and physician about (the management of) possible 
side-effects and about the importance of adherence to guidelines 
are possible strategies to improve guideline compliance. Further-
more, to increase guideline adherence, a guideline should be easy 
accessible, clear and easy to use. Guidelines should be up to date, 
however, on the other hand, a frequently changed guideline may 
hamper guideline adherence. Moreover, differences between e.g., 
the American Urological Association (AUA) [26] and European Asso-
ciation of Urology (EAU) [3] guidelines, however small, are confusing 
and a potential obstacle for guideline adherence. Hopefully, the in-
troduction of the simplified risk group stratification in the 2013 EAU 
guidelines [3], which is more similar to the stratification used in the 
AUA guidelines, will improve guideline compliance.
Improving the efficacy of currently existing intravesical treatments 
is another option to improve NMIBC treatment. Enhancing drug de-
livery to tumour cells could be achieved by controlling physiologic 
variables and by increasing the dose. Relatively simple measures as 
adapting urinary pH, decreasing urinary excretion, and buffering 
the intravesical solution can already enhance efficacy [27].
The efficacy of mitomycin C can also be enhanced using micro-
wave-induced hyperthermia (thermochemotherapy; Synergo) or 
electromotive drug administration (EMDA). These device-assist-
ed therapies facilitate chemotherapeutic drug transport into the 
urothelium and have the potential to improve treatment outcome. 
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Hyperthermia is thought to increase the penetration of mitomy-
cine C into the urothelium due to increased cellular membrane per-
meability and/or modified blood perfusion. In a recent systematic 
review of thermochemotherapy [28], it was reported that thermo-
chemotherapy offered a 59% relative reduction in NMIBC recurrence 
compared with mitomycin C alone, with a bladder preservation rate 
of 87.6%. Currently, there are 2 ongoing phase III trials with thermo-
chemotherapy. In 2002, a multicenter phase III study was started to 
compare 1 year of BCG with 1 year of thermochemotherapy with mi-
tomycin C. A total of 300 high-risk patients will be randomized. Pri-
mary outcome measures are recurrence-free survival, time to com-
plete response (for CIS), and progression rate [29]. Another phase III 
study compares thermochemotherapy with mitomycin C to BCG 
or standard therapy after failure of intravesical therapy. A total of 
242 patients will be randomized to thermochemotherapy and a sec-
ond induction course of BCG with subsequent maintenance for pa-
tients that previously failed induction BCG or standard therapy for 
patients that previously failed maintenance BCG. Standard therapy 
is defined by the treating centers. Primary outcome measures are 
disease-free survival and complete response rates (for CIS) [30]. Most 
clinical thermochemotherapy trials were performed with mitomy-
cin C. However, Van der Heijden et al. [31] investigated the in vitro ef-
fect of hyperthermia on 4 chemotherapeutic agents and found that 
apaziquone was the most potent drug. So future trials investigating 
the effect of thermochemotherapy with apaziquone would also be 
very interesting.
EMDA is mainly based on iontophoresis which represents the elec-
trokinetic migration of ionic molecules in an electric field. A rand-
omized prospective study of EMDA mitomycin C versus passive 
mitomycin C versus standard BCG was conducted in 108 BCG-naïve 
patients with high-risk NMIBC and showed that EMDA mitomycin 
C is equal to BCG in terms of recurrence rate and is significantly su-
perior to passive standard mitomycin C in this patient group [32,33]. 
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Recently, Di Stasi et al. [34] showed that intravesical EMDA mitomy-
cin C before TURBT reduces recurrence rates and enhances the dis-
ease-free interval compared with passive intravesical mitomycin C 
after TURBT and TURBT alone. Currently, device assisted treatment 
modalities are still considered experimental, and predominantly 
used as bladder preservation strategy in patients failing on BCG and 
unfit or unwilling to undergo cystectomy. More phase III trials with 
sufficient follow up are needed to elucidate their role in standard 
NMIBC therapy.
Urothelial carcinoma of the bladder is a heterogeneous disease. It 
ranges from non-muscle invasive to muscle-invasive to advanced dis-
ease. Each clinical state is associated with a unique tumour biology, 
prognosis, and approach to treatment. Non-muscle invasive bladder 
cancer is further stratified in a low, intermediate and high risk group 
based on clinical and pathological factors [3]. Ideally, in the future, 
patients can be offered a personalized treatment of NMIBC reflect-
ing the individual nature of each tumour, intratumour heterogenei-
ty [35], and (epi)genomic background of the patient. Genetic and mo-
lecular profiling of tissue and/or urine may improve risk assignment 
and direct novel targeted treatment strategies to increase efficacy 
and minimize toxicity. Hopefully, future advances in molecular biol-
ogy may accurately predict which treatment will be successful and 
which tumours will not respond to intravesical therapy. For patients 
predicted as non-responders to conservative intravesical treatment 
an early radical cystectomy can be offered, preventing unnecessary 
burden of intravesical treatment and moreover preventing possible 
disease progression in time. For example, Agundez et al. [36] meas-
ured retrospectively the methylation status of 25 tumour suppressor 
genes in 91 patients with T1G3 tumours undergoing BCG treatment. 
It was shown that the combination of MSH6 and THBS1 provided the 
most significant predictive assessment for progression (P = 0.004). 
The promising clinical relevance of tumour suppressor genes meth-
ylation assessment as BCG predictive biomarkers warrants further 
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elucidation in prospective trials to evaluate whether they could sug-
gest therapeutic decisions. In general, an increased armamentarium 
of treatment modalities aiming at different targets, as described 
here, might be valuable to reach the goal of personalized treatment 
of NMIBC patients leading to reduced recurrence and progression 
rates and better quality of life.
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